0001819794
false
2022
Q3
--12-31
September 30, 2022
0001819794
2022-01-01
2022-09-30
0001819794
2022-09-30
0001819794
2021-12-31
0001819794
2021-01-01
2021-09-30
0001819794
ifrs-full:IssuedCapitalMember
2019-12-31
0001819794
ifrs-full:SharePremiumMember
2019-12-31
0001819794
htoo:SharebasedPaymentReserveMember
2019-12-31
0001819794
ifrs-full:RetainedEarningsMember
2019-12-31
0001819794
2019-12-31
0001819794
ifrs-full:IssuedCapitalMember
2020-12-31
0001819794
ifrs-full:SharePremiumMember
2020-12-31
0001819794
htoo:SharebasedPaymentReserveMember
2020-12-31
0001819794
ifrs-full:RetainedEarningsMember
2020-12-31
0001819794
2020-12-31
0001819794
ifrs-full:IssuedCapitalMember
2021-12-31
0001819794
ifrs-full:SharePremiumMember
2021-12-31
0001819794
htoo:SharebasedPaymentReserveMember
2021-12-31
0001819794
ifrs-full:RetainedEarningsMember
2021-12-31
0001819794
ifrs-full:IssuedCapitalMember
2020-01-01
2020-12-31
0001819794
ifrs-full:SharePremiumMember
2020-01-01
2020-12-31
0001819794
htoo:SharebasedPaymentReserveMember
2020-01-01
2020-12-31
0001819794
ifrs-full:RetainedEarningsMember
2020-01-01
2020-12-31
0001819794
2020-01-01
2020-12-31
0001819794
ifrs-full:IssuedCapitalMember
2021-01-01
2021-12-31
0001819794
ifrs-full:SharePremiumMember
2021-01-01
2021-12-31
0001819794
htoo:SharebasedPaymentReserveMember
2021-01-01
2021-12-31
0001819794
ifrs-full:RetainedEarningsMember
2021-01-01
2021-12-31
0001819794
2021-01-01
2021-12-31
0001819794
ifrs-full:IssuedCapitalMember
2022-01-01
2022-09-30
0001819794
ifrs-full:SharePremiumMember
2022-01-01
2022-09-30
0001819794
htoo:SharebasedPaymentReserveMember
2022-01-01
2022-09-30
0001819794
ifrs-full:RetainedEarningsMember
2022-01-01
2022-09-30
0001819794
ifrs-full:IssuedCapitalMember
2022-09-30
0001819794
ifrs-full:SharePremiumMember
2022-09-30
0001819794
htoo:SharebasedPaymentReserveMember
2022-09-30
0001819794
ifrs-full:RetainedEarningsMember
2022-09-30
0001819794
2021-09-30
0001819794
htoo:FusionFuelPortugalMember
2022-01-01
2022-09-30
0001819794
2022-01-01
2022-12-31
0001819794
htoo:ATtheMarketIssuanceSalesAgreementMember
2022-06-01
2022-06-06
0001819794
htoo:ATtheMarketIssuanceSalesAgreementMember
htoo:ClassAOrdinarySharesMember
2022-09-30
0001819794
htoo:ATtheMarketIssuanceSalesAgreementMember
htoo:ClassAOrdinarySharesMember
2022-07-11
2022-09-30
0001819794
htoo:ClassAOrdinarySharesMember
2022-11-14
0001819794
htoo:ClassAOrdinarySharesMember
2022-10-03
2022-11-14
0001819794
2021-08-01
2021-08-05
0001819794
htoo:EmployeesDirectorsAndConsultantsMember
2022-01-01
2022-09-30
0001819794
htoo:EmployeesDirectorsAndConsultantsMember
2021-01-01
2021-09-30
0001819794
htoo:ClassAOrdinarySharesMember
2022-01-01
2022-09-30
0001819794
htoo:ClassAOrdinarySharesMember
htoo:BoardOfDirectorsMember
2022-01-01
2022-09-30
0001819794
htoo:EmployeesAndDirectorsMember
2022-01-01
2022-09-30
0001819794
htoo:EmployeesAndDirectorsMember
2021-01-01
2021-09-30
0001819794
htoo:EmployeeAndDirectorMember
2022-09-30
0001819794
ifrs-full:BottomOfRangeMember
2022-01-01
2022-09-30
0001819794
ifrs-full:TopOfRangeMember
2022-01-01
2022-09-30
0001819794
htoo:OptionsMember
2021-12-31
0001819794
htoo:OptionsMember
2022-01-01
2022-09-30
0001819794
htoo:OptionsMember
2022-09-30
0001819794
htoo:N2020EarnOutMember
2022-01-01
2022-09-30
0001819794
htoo:N2020EarnOutMember
2021-01-01
2021-09-30
0001819794
htoo:RSUsMember
2022-01-01
2022-09-30
0001819794
htoo:RSUsMember
2021-01-01
2021-09-30
0001819794
htoo:IncentiveSharesMember
2022-01-01
2022-09-30
0001819794
htoo:IncentiveSharesMember
2021-01-01
2021-09-30
0001819794
htoo:OptionsMember
2022-01-01
2022-09-30
0001819794
htoo:OptionsMember
2021-01-01
2021-09-30
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:ProductDevelopmentInProgressMember
2021-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:IntellectualPropertyAndPatentsRegistrationMember
2021-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:SoftwareMember
2021-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
2021-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:ProductDevelopmentInProgressMember
2022-01-01
2022-09-30
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:IntellectualPropertyAndPatentsRegistrationMember
2022-01-01
2022-09-30
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:SoftwareMember
2022-01-01
2022-09-30
0001819794
ifrs-full:GrossCarryingAmountMember
2022-01-01
2022-09-30
0001819794
htoo:ProductDevelopmentInProgressMember
ifrs-full:GrossCarryingAmountMember
2022-09-30
0001819794
htoo:IntellectualPropertyAndPatentsRegistrationMember
ifrs-full:GrossCarryingAmountMember
2022-09-30
0001819794
htoo:SoftwareMember
2022-09-30
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
htoo:ProductDevelopmentInProgressMember
2021-12-31
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
htoo:IntellectualPropertyAndPatentsRegistrationMember
2021-12-31
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
htoo:SoftwareMember
2021-12-31
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
2021-12-31
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
htoo:ProductDevelopmentInProgressMember
2022-01-01
2022-09-30
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
htoo:IntellectualPropertyAndPatentsRegistrationMember
2022-01-01
2022-09-30
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
htoo:SoftwareMember
2022-01-01
2022-09-30
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
2022-01-01
2022-09-30
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
htoo:ProductDevelopmentInProgressMember
2022-09-30
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
htoo:IntellectualPropertyAndPatentsRegistrationMember
2022-09-30
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
htoo:SoftwareMember
2022-09-30
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
2022-09-30
0001819794
htoo:ProductDevelopmentInProgressMember
2022-09-30
0001819794
htoo:IntellectualPropertyAndPatentsRegistrationMember
2022-09-30
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:ProductDevelopmentInProgressMember
2020-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:IntellectualPropertyAndPatentsRegistrationMember
2020-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:SoftwareMember
2020-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
2020-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:ProductDevelopmentInProgressMember
2021-01-01
2021-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:IntellectualPropertyAndPatentsRegistrationMember
2021-01-01
2021-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:SoftwareMember
2021-01-01
2021-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
2021-01-01
2021-12-31
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
htoo:ProductDevelopmentInProgressMember
2020-12-31
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
htoo:IntellectualPropertyAndPatentsRegistrationMember
2020-12-31
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
htoo:SoftwareMember
2020-12-31
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
2020-12-31
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
htoo:ProductDevelopmentInProgressMember
2021-01-01
2021-12-31
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
htoo:IntellectualPropertyAndPatentsRegistrationMember
2021-01-01
2021-12-31
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
htoo:SoftwareMember
2021-01-01
2021-12-31
0001819794
ifrs-full:AccumulatedDepreciationAndAmortisationMember
2021-01-01
2021-12-31
0001819794
htoo:ProductDevelopmentInProgressMember
2021-12-31
0001819794
htoo:IntellectualPropertyAndPatentsRegistrationMember
2021-12-31
0001819794
htoo:SoftwareMember
2021-12-31
0001819794
htoo:IntellectualPropertiesMember
2022-01-01
2022-09-30
0001819794
htoo:IntellectualPropertiesMember
2021-01-01
2021-12-31
0001819794
htoo:ProductDevelopmentCostsMember
2022-01-01
2022-09-30
0001819794
htoo:ProductDevelopmentCostsMember
2021-01-01
2021-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:AssetsUnderConstructionMember
2021-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
ifrs-full:OfficeEquipmentMember
2021-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
ifrs-full:RightofuseAssetsMember
2021-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:AssetsUnderConstructionMember
2022-01-01
2022-09-30
0001819794
ifrs-full:GrossCarryingAmountMember
ifrs-full:OfficeEquipmentMember
2022-01-01
2022-09-30
0001819794
ifrs-full:GrossCarryingAmountMember
ifrs-full:RightofuseAssetsMember
2022-01-01
2022-09-30
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:AssetsUnderConstructionMember
2022-09-30
0001819794
ifrs-full:GrossCarryingAmountMember
ifrs-full:OfficeEquipmentMember
2022-09-30
0001819794
ifrs-full:GrossCarryingAmountMember
ifrs-full:RightofuseAssetsMember
2022-09-30
0001819794
ifrs-full:GrossCarryingAmountMember
2022-09-30
0001819794
ifrs-full:AccumulatedImpairmentMember
htoo:AssetsUnderConstructionMember
2021-12-31
0001819794
ifrs-full:AccumulatedImpairmentMember
ifrs-full:OfficeEquipmentMember
2021-12-31
0001819794
ifrs-full:AccumulatedImpairmentMember
ifrs-full:RightofuseAssetsMember
2021-12-31
0001819794
ifrs-full:AccumulatedImpairmentMember
2021-12-31
0001819794
ifrs-full:AccumulatedImpairmentMember
htoo:AssetsUnderConstructionMember
2022-01-01
2022-09-30
0001819794
ifrs-full:AccumulatedImpairmentMember
ifrs-full:OfficeEquipmentMember
2022-01-01
2022-09-30
0001819794
ifrs-full:AccumulatedImpairmentMember
ifrs-full:RightofuseAssetsMember
2022-01-01
2022-09-30
0001819794
ifrs-full:AccumulatedImpairmentMember
2022-01-01
2022-09-30
0001819794
ifrs-full:AccumulatedImpairmentMember
htoo:AssetsUnderConstructionMember
2022-09-30
0001819794
ifrs-full:AccumulatedImpairmentMember
ifrs-full:OfficeEquipmentMember
2022-09-30
0001819794
ifrs-full:AccumulatedImpairmentMember
ifrs-full:RightofuseAssetsMember
2022-09-30
0001819794
ifrs-full:AccumulatedImpairmentMember
2022-09-30
0001819794
htoo:AssetsUnderConstructionMember
2022-09-30
0001819794
ifrs-full:OfficeEquipmentMember
2022-09-30
0001819794
ifrs-full:RightofuseAssetsMember
2022-09-30
0001819794
htoo:AssetsUnderConstructionMember
2021-12-31
0001819794
ifrs-full:OfficeEquipmentMember
2021-12-31
0001819794
ifrs-full:RightofuseAssetsMember
2021-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:AssetsUnderConstructionMember
2020-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
ifrs-full:OfficeEquipmentMember
2020-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
ifrs-full:RightofuseAssetsMember
2020-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
htoo:AssetsUnderConstructionMember
2021-01-01
2021-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
ifrs-full:OfficeEquipmentMember
2021-01-01
2021-12-31
0001819794
ifrs-full:GrossCarryingAmountMember
ifrs-full:RightofuseAssetsMember
2021-01-01
2021-12-31
0001819794
ifrs-full:AccumulatedImpairmentMember
htoo:AssetsUnderConstructionMember
2020-12-31
0001819794
ifrs-full:AccumulatedImpairmentMember
ifrs-full:OfficeEquipmentMember
2020-12-31
0001819794
ifrs-full:AccumulatedImpairmentMember
ifrs-full:RightofuseAssetsMember
2020-12-31
0001819794
ifrs-full:AccumulatedImpairmentMember
2020-12-31
0001819794
ifrs-full:AccumulatedImpairmentMember
htoo:AssetsUnderConstructionMember
2021-01-01
2021-12-31
0001819794
ifrs-full:AccumulatedImpairmentMember
ifrs-full:OfficeEquipmentMember
2021-01-01
2021-12-31
0001819794
ifrs-full:AccumulatedImpairmentMember
ifrs-full:RightofuseAssetsMember
2021-01-01
2021-12-31
0001819794
ifrs-full:AccumulatedImpairmentMember
2021-01-01
2021-12-31
0001819794
htoo:AssetsUnderConstructionMember
2020-12-31
0001819794
ifrs-full:OfficeEquipmentMember
2020-12-31
0001819794
ifrs-full:RightofuseAssetsMember
2020-12-31
0001819794
htoo:ExolumMember
2022-09-30
0001819794
htoo:ExolumMember
2022-01-01
2022-09-30
0001819794
htoo:ExolumMember
ifrs-full:BottomOfRangeMember
2022-01-01
2022-09-30
0001819794
htoo:ExolumMember
ifrs-full:TopOfRangeMember
2022-01-01
2022-09-30
0001819794
htoo:CashAndCashEquivalentMember
2022-09-30
0001819794
htoo:CashAndCashEquivalentMember
ifrs-full:Level1OfFairValueHierarchyMember
2022-09-30
0001819794
htoo:CashAndCashEquivalentMember
ifrs-full:Level2OfFairValueHierarchyMember
2022-09-30
0001819794
htoo:CashAndCashEquivalentMember
ifrs-full:Level3OfFairValueHierarchyMember
2022-09-30
0001819794
htoo:OtherReceivablesMember
2022-09-30
0001819794
htoo:OtherReceivablesMember
ifrs-full:Level1OfFairValueHierarchyMember
2022-09-30
0001819794
htoo:OtherReceivablesMember
ifrs-full:Level2OfFairValueHierarchyMember
2022-09-30
0001819794
htoo:OtherReceivablesMember
ifrs-full:Level3OfFairValueHierarchyMember
2022-09-30
0001819794
htoo:TradePayablesMember
2022-09-30
0001819794
htoo:TradePayablesMember
ifrs-full:Level1OfFairValueHierarchyMember
2022-09-30
0001819794
htoo:TradePayablesMember
ifrs-full:Level2OfFairValueHierarchyMember
2022-09-30
0001819794
htoo:TradePayablesMember
ifrs-full:Level3OfFairValueHierarchyMember
2022-09-30
0001819794
htoo:TradeableWarrantsMember
2022-09-30
0001819794
htoo:TradeableWarrantsMember
ifrs-full:Level1OfFairValueHierarchyMember
2022-09-30
0001819794
htoo:TradeableWarrantsMember
ifrs-full:Level2OfFairValueHierarchyMember
2022-09-30
0001819794
htoo:TradeableWarrantsMember
ifrs-full:Level3OfFairValueHierarchyMember
2022-09-30
0001819794
htoo:OtherPayablesMember
2022-09-30
0001819794
htoo:OtherPayablesMember
ifrs-full:Level1OfFairValueHierarchyMember
2022-09-30
0001819794
htoo:OtherPayablesMember
ifrs-full:Level2OfFairValueHierarchyMember
2022-09-30
0001819794
htoo:OtherPayablesMember
ifrs-full:Level3OfFairValueHierarchyMember
2022-09-30
0001819794
ifrs-full:Level1OfFairValueHierarchyMember
2022-09-30
0001819794
ifrs-full:Level2OfFairValueHierarchyMember
2022-09-30
0001819794
ifrs-full:Level3OfFairValueHierarchyMember
2022-09-30
0001819794
htoo:CashAndCashEquivalentMember
2021-12-31
0001819794
htoo:CashAndCashEquivalentMember
ifrs-full:Level1OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:CashAndCashEquivalentMember
ifrs-full:Level2OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:CashAndCashEquivalentMember
ifrs-full:Level3OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:FinancialAssetsAtFVTPLMember
2021-12-31
0001819794
htoo:FinancialAssetsAtFVTPLMember
ifrs-full:Level1OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:OtherReceivablesMember
2021-12-31
0001819794
htoo:OtherReceivablesMember
ifrs-full:Level1OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:OtherReceivablesMember
ifrs-full:Level2OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:OtherReceivablesMember
ifrs-full:Level3OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:TradePayablesMember
2021-12-31
0001819794
htoo:TradePayablesMember
ifrs-full:Level1OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:TradePayablesMember
ifrs-full:Level2OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:TradePayablesMember
ifrs-full:Level3OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:TradeableWarrantsMember
2021-12-31
0001819794
htoo:TradeableWarrantsMember
ifrs-full:Level1OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:TradeableWarrantsMember
ifrs-full:Level2OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:TradeableWarrantsMember
ifrs-full:Level3OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:OtherPayablesMember
2021-12-31
0001819794
htoo:OtherPayablesMember
ifrs-full:Level1OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:OtherPayablesMember
ifrs-full:Level2OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:OtherPayablesMember
ifrs-full:Level3OfFairValueHierarchyMember
2021-12-31
0001819794
ifrs-full:Level1OfFairValueHierarchyMember
2021-12-31
0001819794
ifrs-full:Level2OfFairValueHierarchyMember
2021-12-31
0001819794
ifrs-full:Level3OfFairValueHierarchyMember
2021-12-31
0001819794
htoo:WarrantsMember
2022-01-01
2022-09-30
0001819794
htoo:WarrantsMember
2021-01-01
2021-09-30
0001819794
htoo:RSUOutstandingMember
2022-01-01
2022-09-30
0001819794
htoo:RSUOutstandingMember
2021-01-01
2021-09-30
0001819794
htoo:RsuVestedMember
2022-01-01
2022-09-30
0001819794
htoo:RsuVestedMember
2021-01-01
2021-09-30
0001819794
htoo:IncentiveSharesMember
2022-01-01
2022-09-30
0001819794
htoo:IncentiveSharesMember
2021-01-01
2021-09-30
0001819794
htoo:ShareOptionsMember
2022-01-01
2022-09-30
0001819794
htoo:ShareOptionsMember
2021-01-01
2021-09-30
0001819794
htoo:OrdinaryShareMember
htoo:EarnOut2020Member
2022-01-01
2022-09-30
0001819794
htoo:OrdinaryShareMember
htoo:EarnOut2020Member
2021-01-01
2021-09-30
0001819794
htoo:WarrantsMember
htoo:EarnOut2020Member
2022-01-01
2022-09-30
0001819794
htoo:WarrantsMember
htoo:EarnOut2020Member
2021-01-01
2021-09-30
0001819794
htoo:FuelCellEvoraUnipessoalMember
2022-01-01
2022-09-30
0001819794
htoo:FuelCellEvoraIUnipessoalMember
2022-01-01
2022-09-30
0001819794
htoo:FusionFuelUSAMember
2022-01-01
2022-09-30
0001819794
htoo:FusionFuelSpainMember
2022-01-01
2022-09-30
0001819794
htoo:FusionFuelAustraliaPTYLtdMember
2022-01-01
2022-09-30
0001819794
htoo:FusionFuelAustraliaPilotPTYLtdMember
2022-01-01
2022-09-30
0001819794
htoo:HevoSinesUnipessoalLDAMember
2022-01-01
2022-09-30
0001819794
htoo:HevoSinesIIUnipessoalLDAMember
2022-01-01
2022-09-30
0001819794
htoo:HevoSinesIIIUnipessoalLDAMember
2022-01-01
2022-09-30
iso4217:EUR
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
iso4217:USD
iso4217:EUR
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of: December 2022
Commission File Number: 005-91913
Fusion Fuel Green PLC
(Translation of registrant’s name
into English)
The Victorians
15-18 Earlsfort Terrace
Saint Kevin’s
Dublin 2, D02 YX28, Ireland
(Address
of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits the submission
in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and
make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s
“home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as
long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s
security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing
on EDGAR.
This Report of Foreign Private Issuer on Form 6-K (“Form
6-K”) of Fusion Fuel Green PLC (“we,” “our,” “us,” the “Company,” “Parent”
or “Fusion Fuel” and together with its subsidiaries collectively referred to herein as the “Group”) contains
certain business and operational updates for the Company as well as certain financial information. The information contained in this Form
6-K shall be incorporated by reference in the Company’s registration statement on Form F-3 (File No. 333-264714) and the prospectus
and any prospectus supplements included therein.
Changes
in Application of Home Country Practice Rules
As
a foreign private issuer, the Company is permitted to follow home country practice (Irish law) in lieu of the otherwise applicable corporate
governance requirements under the Nasdaq Listing Rules, subject to certain exceptions. In order to rely on home country practice, the
Company is required to disclose each corporate governance requirement under the Nasdaq Listing Rules that the Company does not follow
and describe the home country practice the Company does follow in lieu thereof.
The
Company has elected to follow corporate governance practices under Irish law in lieu of the requirements of Nasdaq Rule 5635(c) and 5635(d)(2),
which require companies to obtain shareholder approval prior to the issuance of securities to officers, directors, employees or consultants
under certain circumstances and when it seeks to engage in a transaction, other than a public offering, involving the sale, issuance or
potential issuance of ordinary shares, which alone or together with sales by officers, directors or substantial shareholders of the company,
equals 20% or more of the ordinary shares or 20% or more of the voting power outstanding before the issuance at a price below a certain
price indicated in such Nasdaq Rule. Irish law and generally accepted business practices in Ireland do not require that shareholders approve
such transactions. Accordingly, shareholder approval is not required for these types of transactions by the Company.
Business
Update
Since
the filing of the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2021, the Company has announced and/or
entered into several significant milestones or agreements. These include:
|
· |
On May 19, 2022, the Company announced that it had signed a Memorandum
of Understanding with Toshiba Energy Systems and Solutions Corporation (“Toshiba ESS”), which provides a framework for the
companies to pursue technical and commercial collaboration in the green hydrogen sector. Pursuant to the Memorandum of Understanding,
the Company would evaluate the use of Toshiba ESS’ membrane electrode assemblies (“MEAs”) within its HEVO micro-electrolyzers,
and Toshiba ESS would explore using the local sales channels it has developed in areas such as the thermal power business to expand sales
of the Company’s PEM electrolyzers in Australia and other countries. The two companies also agreed to explore potential collaboration
opportunities for future sales of Toshiba ESS’ solid oxide electrolysis cells, which Toshiba ESS targets bringing to market in 2025.
The two companies have been working together on the testing and adaption of the Toshiba membrane to fit with the HEVO technology. Testing
to determine whether this can be accomplished for mass scale production is expected to be finished in the first quarter of 2023. If it
can be accomplished, the parties will look to move to mass scale production during the first half of 2023. |
|
· |
In June 2022, the Company completed installation of the HEVO production
line at the Company’s Benavente facility in Portugal. The Company expects to achieve 100 megawatts (“MW”) of electrolyzer
production capacity in 2023, which is expected to increase to approximately 500 MW in 2025. In November 2022, the Company completed the
installation of a 1 MW solar array on the roof of the Benavente factory at its facility. |
|
· |
In June 2022, the Company engaged TUV SUD, an association of experts
that provides safety, security, and sustainability solutions, to perform a twelve-month performance audit of the Company’s HEVO-Solar
technology system. As of the most recent interim report provided to the Company in November 2022, the overall system (Solar to Hydrogen)
is performing in excess of 15% above the product data sheet specifications. The Company also retained Black & Veatch Management Consulting,
LLC to perform an independent assessment of the HEVO-Solar Hydrogen Generator and the Company’s ability to consistently deliver
the HEVO-Solar technology with the quality required to meet its technical specifications. That project was successfully completed in August
2022. |
|
· |
On June 6, 2022, the Company entered into an At the Market Issuance
Sales Agreement (the “ATM”) with B. Riley Securities, Inc., Fearnley Securities Inc. and H.C. Wainwright & Co., LLC, for
the potential issuance of up to $30 million of the Company’s class A ordinary shares. Between July 11, 2022, and November 14, 2022,
the Company sold an aggregate of 681,926 class A ordinary shares pursuant to the ATM for aggregate net proceeds to the Company of $3,685,792. |
|
· |
On June 23, 2022,
the Company announced that its “Sines Green Hydrogen Valley Alliance” had been selected by the Agenda Coordination Commission
to advance to final negotiations for grant funding through Component 5 of the Portuguese Recovery and Resilience Plan. The centerpiece
of the Sines Green Hydrogen Valley Alliance is the Company’s H2 HEVO-SINES project, a 3,000 HEVO-Solar unit facility – equivalent
to 75 MW of electrolysis capacity – that is expected to reach final investment decision in 2024. On December 7, 2022, the Company
announced that it had completed the financing discussions and submitted the terms of acceptance for €36 million in grant funding
secured by the Sines Green Hydrogen Valley Alliance. Of the €36 million awarded to the consortium, €22.5 million is to be allocated
to the Company’s H2 HEVO-SINES project, and €3.5 million is to be allocated to the Company to fund research and development
of its proprietary electrolysis technology. The balance of the funding will be allocated to other projects within the Company’s
consortium for which the Company is a technology partner, including those sponsored by KEME Energy, Transition2Green, and HyLAB Collaborative
Laboratory. |
| · | On August 18, 2022, the Company announced that it had been approved
for an estimated €10 million in grant funding through Component 14 of the Portuguese Recovery and Resilience Plan to develop its
6.6MW HEVO-Industria green hydrogen project in Sines, Portugal. The €25 million, 300 HEVO-Solar unit project is expected to reach
final investment decision in the first half of 2023. |
|
· |
On September 29, 2022, the Company announced that it had entered into
a €5 million contract with Gedisol Energiá, Sociedad Limitada, a Spanish developer,
to supply technology for a 144 HEVO-Solar unit, 3.2 MW green hydrogen project to be developed in Andalucía, Spain, which would
produce an estimated 200 tonnes of green hydrogen per year. |
|
· |
On October 6, 2022, the Company announced that it had entered into a
€2 million contract with KEME Energy to supply technology for a 62 HEVO-Solar unit, 1.2 MW green hydrogen project in Sines, Portugal.
The Company and KEME had previously announced the execution of a collaboration agreement in February 2022. |
|
· |
On November 10, 2022, the Company and Ballard Power Systems (“Ballard”)
announced the successful commissioning of the Company’s H2Évora plant. H2Évora is Portugal’s first solar-to-green
hydrogen facility and first fully integrated hydrogen-to-power demonstration project. The 15 HEVO-Solar unit facility includes a 200-kilowatt
FCwaveTM fuel cell module supplied by Ballard, which is used to convert green hydrogen into electricity, enabling the Company to sell
power into the electric grid during periods of peak demand. |
|
· |
On November 18, 2022, the Company announced that it had entered into
a commercial agreement with Duferco Energia SpA (“Duferco”) to jointly develop the green hydrogen ecosystem in Italy. The
inaugural project under the agreement is a 1.25 MW green hydrogen pilot project to be developed at Duferco’s industrial site in
Giammoro, Sicily. The Company is expected to supply 50 of its HEVO-Solar trackers for the proposed project, which would be installed in
the first half of 2024. The broader objective of the commercial agreement is to build a pipeline of project development opportunities
and turnkey technology-sale projects, leveraging Duferco’s local sales network, knowledge of local markets, and extensive shipping
and logistics’ expertise. |
|
· |
On November 21, 2022, the Company announced its involvement as a technology
provider in four projects that had been pre-selected for up to €12.9 million in grant funding through H2 Pioneros, a funding call
under the Strategic Projects for Economic Recovery and Transformation (“PERTE”) program in Spain. The four projects are expected
to generate €31.7 million in revenue, of which an estimated €16.4 million would be derived from the sale of the Company’s
technology. |
|
· |
On November 23, 2022, the Company introduced its HEVO-Chain system,
marking its entry into the centralized electrolyzer market. The HEVO-Chain hydrogen unit consists of 16 HEVO micro-electrolyzers interconnected
along a string, representing 11.2 kW of electrolysis capacity and outputting 5.6 kg of hydrogen per day at a pressure of 4 bar. The HEVO-Chain
system is designed for a standard 19” rack cabinet, allowing for up to eight units to be integrated seamlessly alongside the power
electronics and water purification system. The HEVO-Chain is currently undergoing comprehensive performance and reliability testing and
the first units are expected to enter commercial use in the second half of 2024. The Company also submitted a patent application associated
with the HEVO-Chain technology. |
|
· |
On November 28, 2022,
the Company announced that it had entered into an exclusive joint venture agreement with Electus Energy to develop a 75 MW, $180 million
green hydrogen project in Bakersfield, California. The project would be capable of producing up to 9,300 tons of green hydrogen per year
including nighttime operation, and the Company expects to reach final investment decision in early 2024 and commission the project in
the first half of 2025. The Bakersfield project is the cornerstone of the Company’s US commercial strategy, which is focused on
opportunities in hydrogen mobility and logistics. |
Except
for the project with Exolum Corporation, S.A. (“Exolum”) previously announced and further discussed herein, the Company is
currently under no obligation to proceed with, and therefore no penalties or liabilities would be imposed on the Company with respect
to, any of the projects set forth above if the Company determines, for any reason, not to proceed with such project. With respect to
projects where the Company or its partners have been awarded grants, they are only required to either proceed or reimburse any funds
received if grant funds have actually been transferred to the Company. The Company only commits to a project when definitive contracts
with the hydrogen off-taker or the technology buyer are signed. In determining whether to proceed with a project, the Company considers
several factors including, but not limited to, timing to completion, project financials and target return, relationship with the partner
or client and the production capacity available. Accordingly, other than the Exolum project, there can be no assurance that the Company
will actually proceed with any of the projects set forth above.
In
addition, as previously announced, we are in continual negotiations with third parties to fund our operations. Although discussions and
negotiations continue to progress with such third parties, including in some cases the execution of non-binding letters of intent or term
sheets, none have reached the stage of executed definitive agreements at this time. As negotiations are fluid, it is possible that any
particular negotiation could accelerate or be abandoned at any time. An announcement of any material agreement with a third party would
be made when and if a material definitive agreement is reached with such third party.
Financial
Information
The
following is the Company’s unaudited interim condensed consolidated financial statements for the nine months ended September 30,
2022 and 2021, and related management’s discussion and analysis discussing such financial statements.
Nine Months Ended September 30, 2022
Condensed consolidated statements of financial position (Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
As at |
|
|
|
|
September 30,
2022 |
|
|
|
December 31,
2021
(Audited)
|
|
|
|
|
€’000 |
|
|
|
€’000 |
|
Non-current assets |
|
|
|
|
|
|
|
|
Intangible assets |
|
|
5,281 |
|
|
|
3,847 |
|
Property, plant and equipment |
|
|
28,267 |
|
|
|
18,111 |
|
Total non-current assets |
|
|
33,548 |
|
|
|
21,958 |
|
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Inventory |
|
|
12,053 |
|
|
|
3,685 |
|
Prepayments and other receivables |
|
|
10,873 |
|
|
|
8,472 |
|
Financial assets at fair value through profit or loss |
|
|
— |
|
|
|
27,453 |
|
Cash and cash equivalents |
|
|
3,610 |
|
|
|
7,681 |
|
Total current assets |
|
|
26,536 |
|
|
|
47,291 |
|
|
|
|
|
|
|
|
|
|
Total assets |
|
|
60,084 |
|
|
|
69,249 |
|
|
|
|
|
|
|
|
|
|
Non-current liabilities |
|
|
|
|
|
|
|
|
Trade and other payables – lease liability |
|
|
904 |
|
|
|
411 |
|
Total non-current liabilities |
|
|
904 |
|
|
|
411 |
|
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Trade and other payables |
|
|
3,416 |
|
|
|
2,877 |
|
Provisions |
|
|
709 |
|
|
|
— |
|
Derivative financial instruments - warrants |
|
|
9,736 |
|
|
|
15,271 |
|
Accrued expenses |
|
|
1,558 |
|
|
|
1,178 |
|
Total current liabilities |
|
|
15,419 |
|
|
|
19,326 |
|
|
|
|
|
|
|
|
|
|
Total liabilities |
|
|
16,323 |
|
|
|
19,737 |
|
|
|
|
|
|
|
|
|
|
Net assets |
|
|
43,761 |
|
|
|
49,512 |
|
|
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
|
Share capital |
|
|
2 |
|
|
|
2 |
|
Share premium |
|
|
215,651 |
|
|
|
213,477 |
|
Share-based payments reserve |
|
|
3,096 |
|
|
|
463 |
|
Retained earnings |
|
|
(174,988 |
) |
|
|
(164,430 |
) |
Total equity |
|
|
43,761 |
|
|
|
49,512 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
Condensed consolidated statements of profit or loss and other comprehensive income (Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
For the nine months ended September
30, 2022 |
|
|
|
For the nine months ended September
30, 2021 |
|
|
|
|
€’000 |
|
|
|
€’000 |
|
Revenue |
|
|
— |
|
|
|
— |
|
Cost of sales |
|
|
(1,172 |
) |
|
|
— |
|
Gross loss |
|
|
(1,172 |
) |
|
|
— |
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
|
Administration expenses |
|
|
(11,572 |
) |
|
|
(4,920 |
) |
Share-based payment expense |
|
|
(2,633 |
) |
|
|
(14,688 |
) |
Onerous contract provision |
|
|
(709 |
) |
|
|
— |
|
Operating loss |
|
|
(16,086 |
) |
|
|
(19,608 |
) |
|
|
|
|
|
|
|
|
|
Net finance income |
|
|
|
|
|
|
|
|
Finance income |
|
|
600 |
|
|
|
2,143 |
|
Finance costs |
|
|
(51 |
) |
|
|
— |
|
Fair value movement on derivatives |
|
|
5,535 |
|
|
|
15,883 |
|
Net finance income |
|
|
6,084 |
|
|
|
18,026 |
|
|
|
|
|
|
|
|
|
|
Share of losses of equity-accounted investees |
|
|
(522 |
) |
|
|
— |
|
|
|
|
|
|
|
|
|
|
Loss before tax |
|
|
(10,524 |
) |
|
|
(1,582 |
) |
Income tax expense |
|
|
(34 |
) |
|
|
— |
|
Total comprehensive loss |
|
|
(10,558 |
) |
|
|
(1,582 |
) |
|
|
|
|
|
|
|
|
|
Basic and diluted (loss) per share |
|
|
(0.80 |
) |
|
|
(0.12 |
) |
The accompanying notes are an integral part of these condensed consolidated financial statements.
Condensed consolidated statement of changes in equity (Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares outstanding |
|
|
|
Share capital |
|
|
|
Share premium |
|
|
|
Share-based payment reserve |
|
|
|
Retained earnings |
|
|
|
Total |
|
|
|
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at January 1, 2020 |
|
|
2,125,000 |
|
|
|
— |
|
|
|
3 |
|
|
|
— |
|
|
|
(2 |
) |
|
|
1 |
|
Loss during the year |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
(183,130 |
) |
|
|
(183,130 |
) |
Issue of share capital: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HL Acquisition Transaction |
|
|
7,033,356 |
|
|
|
1 |
|
|
|
139,027 |
|
|
|
— |
|
|
|
(3,566 |
) |
|
|
135,462 |
|
PIPE Financing |
|
|
2,450,000 |
|
|
|
— |
|
|
|
48,429 |
|
|
|
— |
|
|
|
(1,430 |
) |
|
|
46,999 |
|
Exercise of warrants |
|
|
445,861 |
|
|
|
— |
|
|
|
4,178 |
|
|
|
— |
|
|
|
— |
|
|
|
4,178 |
|
Derecognition of warrant liability on exercise |
|
|
— |
|
|
|
— |
|
|
|
2,416 |
|
|
|
— |
|
|
|
— |
|
|
|
2,416 |
|
Share based payments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity-settled share-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,438 |
|
|
|
— |
|
|
|
1,438 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2020 |
|
|
12,054,217 |
|
|
|
1 |
|
|
|
194,053 |
|
|
|
1,438 |
|
|
|
(188,128 |
) |
|
|
7,364 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at January 1, 2021 |
|
|
12,054,217 |
|
|
|
1 |
|
|
|
194,053 |
|
|
|
1,438 |
|
|
|
(188,128 |
) |
|
|
7,364 |
|
Profit during the year |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
23,564 |
|
|
|
23,564 |
|
Total comprehensive income for the year |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
23,564 |
|
|
|
23,564 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issue of share capital: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vesting of shares |
|
|
10,000 |
|
|
|
— |
|
|
|
— |
|
|
|
(134 |
) |
|
|
134 |
|
|
|
— |
|
Exercise of warrants |
|
|
1,059,506 |
|
|
|
1 |
|
|
|
10,050 |
|
|
|
— |
|
|
|
— |
|
|
|
10,051 |
|
Derecognition of warrant liability on exercise |
|
|
— |
|
|
|
— |
|
|
|
9,374 |
|
|
|
— |
|
|
|
— |
|
|
|
9,374 |
|
Share based payments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity-settled share-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(841 |
) |
|
|
— |
|
|
|
(841 |
) |
Balance at December 31, 2021 |
|
|
13,123,723 |
|
|
|
2 |
|
|
|
213,477 |
|
|
|
463 |
|
|
|
(164,430 |
) |
|
|
49,512 |
|
Loss during the period |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(10,558 |
) |
|
|
(10,558 |
) |
Total comprehensive income for the year |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(10,558 |
) |
|
|
(10,558 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issue of share capital: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of ordinary shares |
|
|
295,269 |
|
|
|
— |
|
|
|
2,174 |
|
|
|
— |
|
|
|
— |
|
|
|
2,174 |
|
Share based payments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity-settled share-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2,633 |
|
|
|
— |
|
|
|
2,633 |
|
Balance at September 30, 2022 |
|
|
13,418,992 |
|
|
|
2 |
|
|
|
215,651 |
|
|
|
3,096 |
|
|
|
(174,988 |
) |
|
|
43,761 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
Condensed consolidated statements of cash flows (Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
For the 9 months ended September
30 |
|
|
|
|
2022 |
|
|
|
2021 |
|
|
|
|
€’000 |
|
|
|
€’000 |
|
Cash flows from operating activities |
|
|
|
|
|
|
|
|
Net profit/ (loss) for the year |
|
|
(10,557 |
) |
|
|
(1,582 |
) |
Adjusted for: |
|
|
|
|
|
|
|
|
Equity settled share-based payment transactions |
|
|
2,633 |
|
|
|
14,688 |
|
Fair value movement in warrants |
|
|
(5,535 |
) |
|
|
(15,883 |
) |
Depreciation and amortization |
|
|
428 |
|
|
|
(221 |
) |
Net finance income |
|
|
(578 |
) |
|
|
(2,143 |
) |
Share of losses of equity-accounted investee |
|
|
522 |
|
|
|
— |
|
Impairment charge - inventory |
|
|
1,172 |
|
|
|
— |
|
Onerous contract provision |
|
|
709 |
|
|
|
— |
|
Total Adjusted |
|
|
(11,206 |
) |
|
|
(5,141 |
) |
Changes in working capital: |
|
|
|
|
|
|
|
|
(Increase) in receivables |
|
|
(1,598 |
) |
|
|
(6,508 |
) |
(Increase) in inventories |
|
|
(9,540 |
) |
|
|
(3,419 |
) |
Increase in payables and accruals |
|
|
(995 |
) |
|
|
(556 |
) |
Interest paid |
|
|
(21 |
) |
|
|
— |
|
Net cash used by operating activities |
|
|
(23,360 |
) |
|
|
(15,624 |
) |
|
|
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
|
|
Payment for intellectual property from 2020 business combination |
|
|
(250 |
) |
|
|
(500 |
) |
Purchase of property, plant and equipment |
|
|
(8,395 |
) |
|
|
(9,222 |
) |
Development expenditure |
|
|
(1,404 |
) |
|
|
(857 |
) |
Purchase of intangible assets – other |
|
|
(42 |
) |
|
|
(10 |
) |
Purchase of financial assets |
|
|
— |
|
|
|
(44,328 |
) |
Proceeds from realisation of financial assets |
|
|
27,893 |
|
|
|
10,951 |
|
Investment in equity-accounted investees |
|
|
(522 |
) |
|
|
— |
|
Net cash from /(used) in investing activities |
|
|
17,280 |
|
|
|
(43,966 |
) |
|
|
|
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
|
|
|
|
Proceeds from issuance of shares |
|
|
2,174 |
|
|
|
— |
|
Proceeds from warrants exercised |
|
|
— |
|
|
|
10,051 |
|
Payment of lease liabilities |
|
|
(302 |
) |
|
|
(228 |
) |
Net cash provided by financing activities |
|
|
1,872 |
|
|
|
9,823 |
|
|
|
|
|
|
|
|
|
|
Net (decrease)/increase in cash and cash equivalents |
|
|
(4,208 |
) |
|
|
(49,767 |
) |
Cash and cash equivalents at beginning of period |
|
|
7,681 |
|
|
|
58,007 |
|
Effects of movements in exchange rates on cash held |
|
|
137 |
|
|
|
(365 |
) |
Cash and cash equivalents at end of period |
|
|
3,610 |
|
|
|
7,875 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
Notes forming part of the unaudited condensed consolidated financial statements for the nine
months ended September 30, 2022.
1. |
Summary of significant accounting policies |
Business activity
Fusion Fuel Green PLC (the “Parent” or “Company”)
was incorporated in Ireland on April 3, 2020. The Company and its subsidiaries are collectively referred to as the “Group”.
The registered office of the Company is The Victorians, 15-18 Earlsfort Terrace, Saint Kevin’s, Dublin 2, D02 YX28, Ireland.
The Group’s mission is to produce hydrogen with zero carbon
emissions, thereby contributing to a future of sustainable and affordable clean energy and the reversal of climate change. The hydrogen
will be produced using renewable energy resulting in zero carbon emissions (“Green Hydrogen”) with components built in-house
and using the know-how and accumulated experience of its team’s strategic and continuous investment in research and development
(“R&D”) around solar technologies.
The Company has a well-established risk management process which
is managed through its management team, finance committee and board of directors. The key risks are evaluated throughout the period with
key business leaders tasked to manage each risk as required. These risks are assessed through a risk matrix which evaluates each risk’s
impact and likelihood.
Basis of presentation
The unaudited condensed consolidated financial statements are
prepared in accordance with International Accounting Standard 34 “Interim Financial Reporting” (IAS 34). In the opinion of
the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring
in nature, necessary for fair financial statement presentation. The condensed consolidated financial statements and accompanying notes
were prepared in conformity with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting
Standards Board (“IASB”) which requires management to make estimates and assumptions that affect the amounts reported. Actual
results could differ materially from those estimates. These condensed consolidated financial statements and accompanying notes should
be read in conjunction with the Group’s annual consolidated financial statements and accompanying notes included in its Annual Report
on Form 20-F for the fiscal year ended December 31, 2021 (the “2021 Form 20-F”). These condensed consolidated financial statements
are presented in Euro, the functional and presentation currency of the Company. All financial information presented in euro has been rounded
to the nearest thousand, unless otherwise stated.
As a result of rounding, numbers or percentages may not add up
to the total.
Use of estimates
Preparation of condensed consolidated financial statements in
conformity with IFRS requires the use of estimates and judgments that affect the reported amounts in the condensed consolidated financial
statements and accompanying notes. IFRS requires the Company to make estimates and judgments in several areas, including, but not limited
to, revenue, expenses, assets and liabilities, income taxes and the accompanying disclosures. Significant estimates and assumptions reflected
in these condensed consolidated financial statements include, but are not limited to, the valuation of derivatives, the valuation of share-based
compensation awards, and the valuation of the intangible assets. The Company bases its estimates on historical experience, known trends
and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management
evaluates its estimates as there are changes in circumstances, facts and experience. Actual results could differ materially from those
estimates.
Significant accounting policies
There have been no material changes to the Company’s significant
accounting policies as compared to the significant accounting policies described in the 2021 Form 20-F other than the introduction of
an accounting policy for provision for onerous contracts. See note 9 for further information.
New standards or amendments
There were no new standards effective for the period commencing
1 January 2022 that had a material impact on the Group. A number of new standards, amendments to standards and interpretations are not
yet effective for the period and have not yet been applied in preparing the unaudited condensed consolidated financial statements. The
Group is in the process of assessing the impact on the financial statements of these new standards and amendments. Management currently
expects no material impact on the Group’s financial statements on adoption of these amendments.
Segment information
The Group manages its operations as a single segment for purposes
of assessing performance and making operating decisions. The Group’s focus is on the research and development around solar technologies.
The Executive Committee, and in particular the Chief Financial Officer, is the chief operating decision maker that regularly reviews the
consolidated operating results and makes decisions about the allocation of the Group’s resources.
Going concern
As of September 30, 2022, the Group had €3.6 million of cash and cash equivalents.
The Group has incurred operating losses since inception and had an accumulated deficit of €174.99 million at September 30, 2022. The
Group expects to continue to incur net losses for the foreseeable future and is highly dependent on its ability to find additional sources
of funding in the form of debt or equity financing to fund its planned operations. These conditions raise significant doubt about the
Group’s ability to continue as a going concern absent the mitigating actions set out below.
Management believes that its cash and cash equivalents of €3.6 million at September
30, 2022 and the receipt of anticipated grant funding, proposed sale and leaseback of its production facility, drawdown of a working capital
credit facility and forecasted project related revenues will provide sufficient liquidity to fund operations for at least one year after
the date the financial statements are issued. In making this assessment, management has considered the Group’s available cash resources,
expected inflows between now and the end of the first quarter of 2023, future financing options available to the Group, the planned operations
of the Group and the ability to adjust its plans if required. Subsequent to September 30, 2022, the Group has received €3.17 million
of the VAT receivable balance shown in note 7 with a further €0.6 million of this balance approved for payment before December 31,
2022. As part of its assessment, management has considered the following key adjustments: (i) receipt of anticipated inflows relating
to an impending transaction for the sale and leaseback of its production facility with an independent third party which is expected to
close by December 31, 2022 and result in anticipated net inflows of between approximately €7.5 million and €8.5 million; and
(ii) the Group is in advanced discussions with a Portuguese based financial institution regarding a working capital credit facility, which,
if entered into, would provide liquidity of approximately €2.5 million.
Additionally, as previously announced, the Group is in continual negotiations with
third parties to fund its operations, as well as exploring all available sources of financing. Although negotiations have progressed
to a degree with certain of such third parties, including in some cases to the point of signed letters of intent or term sheets, none
have reached the stage of executed definitive agreements at this time. As negotiations are fluid, it is possible that any particular
negotiation could accelerate or be abandoned at any time. An announcement of any material agreement with a third party would be
made when and if a binding agreement is reached with such third party. The inability to obtain funding, as and when needed, would have
a negative impact on the Group’s financial conditions and ability to pursue its business strategies. If the Group is unable to obtain
funding, the Group could be forced to delay, reduce, or eliminate some or all of its research and development programs or strategic partnerships
efforts, which could adversely affect its business prospects, or the Group may be unable to continue operations. Although management intends
to pursue plans to obtain additional funding to finance its operations, there is no assurance that the Group will be successful in obtaining
sufficient funding on terms acceptable to the Group to fund continuing operations, if at all.
The accompanying unaudited condensed consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty. Accordingly, the unaudited condensed consolidated financial statements
have been prepared on a basis that assumes the Group will continue as a going concern and which contemplates the realization of assets
and satisfaction of liabilities and commitments in the ordinary course of business.
At the Market Issuance Sales Agreement
On June 6, 2022, Parent entered into an At the Market Issuance Sales Agreement (“the
ATM”) with B. Riley Securities, Inc., Fearnley Securities Inc., and H.C. Wainwright & Co., LLC, pursuant to which the Company
may offer and sell, from time to time, through or to the agents, acting as agent or principal, Class A ordinary shares of the Company
having an aggregate offering price of up to $30 million under the Company’s Form F-3 registration statement. Between July 11, 2022,
and September 30, 2022, we sold 295,269 class A ordinary shares for net proceeds of $2,204,959 at an average sales price of $7.35 per
share. We paid $66,149 in commissions to agents as part of these trades. Between October 3, 2022 and November 14, 2022, we sold 386,657
class A ordinary shares for net proceeds of $1,480,833 at an average sales price of $4.02 per share. We paid $44,425 in commissions to
agents as part of these trades.
2021 Equity Incentive Plan
On August 5, 2021, the Company’s Board of Directors adopted
and approved the 2021 Equity Incentive Plan (the 2021 Plan), which authorized the Company to grant up to 1,000,000 Class A ordinary
shares in the form of incentive share options, non-qualified share options, share appreciation rights, restricted awards, performance
share awards, cash awards and other share awards. The types of share-based awards, including the rights amount, terms, and exercisability
provisions of grants are determined by the Company’s Board of Directors.
Restricted Share Units (RSUs)
The Company granted 59,441 RSUs to employees, directors and
consultants during the nine month period ended September 30, 2022 (2021: None). The table below shows the number of RSUs granted covering
an equal number of the Company’s Class A ordinary shares and the weighted-average grant date fair value of the RSUs granted:
Schedule of Restricted share units |
|
|
|
|
|
|
|
|
|
|
|
Number of RSUs |
|
Weighted average Grant date
fair value per share |
RSUs outstanding December 31, 2020 |
|
|
|
— |
|
|
$ |
— |
|
Granted |
|
|
|
57,896 |
|
|
$ |
12.24 |
|
Vested (1) |
|
|
|
(15,000 |
) |
|
$ |
12.24 |
|
Forfeited |
|
|
|
— |
|
|
|
— |
|
RSUs outstanding December 31, 2021 |
|
|
|
42,896 |
|
|
$ |
12.24 |
|
Granted |
|
|
|
59,441 |
|
|
$ |
8.51 |
|
Vested (1) |
|
|
|
(5,853 |
) |
|
$ |
— |
|
Forfeited |
|
|
|
— |
|
|
|
— |
|
RSUs outstanding September 30, 2022 |
|
|
|
96,484 |
|
|
$ |
11.43 |
|
|
(1) |
No ordinary shares were issued in connection with the RSUs that vested during the nine month period ended
September 30, 2022 and the year ended December 31, 2021. |
The fair value of the RSUs is determined on the date of grant
based on the market price of the Company’s ordinary shares on that date. The fair value of RSUs is expensed rateably over the vesting
period, which is generally three years for employees and consultants. The total expense recognized related to the RSUs was €0.41
million for the period ended September 30, 2022 (2021: €0.17 million). Total unamortized compensation expense related to the RSUs
was €0.47 million as of September 30, 2022, which is expected to be recognized over a remaining average vesting period of 1.9 years
as of September 30, 2022.
Share options
On January 3, 2022, the Company announced that under the 2021
Plan, its Board of Directors (the “Board”) approved an award of options for five of its senior managers. With regard to each
senior manager, the award is comprised of three elements:
|
· |
A grant of an option to purchase 200,000 Class A ordinary shares having an exercise price of $10.50 per share
to vest over a three-year period. |
|
· |
A grant of an option to purchase an additional 200,000 Class A ordinary shares having an exercise price of
$10.50 per share to vest once Parent’s share price closed at or above $18.00 during twenty trading days out of any thirty consecutive
trading day period. |
|
· |
Eligibility to receive an option to purchase up to an additional 50,000 Class A ordinary shares having an
exercise price equal to the average last sales price of the Class A ordinary shares over the five (5) consecutive trading day period ending
on the date of grant, but in no event to be lower than $10.50 per share, for each of calendar years 2022, 2023 and 2024, each to be granted
based on individual performance at the discretion of the Compensation Committee of the board of directors. |
All options granted will expire on December 31, 2028.
The Company granted 2,128,554 options to employees, directors and consultants during the nine
month period ended September 30, 2022 (2021: None).
The fair value of the options granted during the nine month period
ended September 30, 2022 were estimated using the Black-Scholes option-pricing model. The inputs for the Black-Scholes model require
management’s significant assumptions. The risk-free interest rate was based on a normalized estimate of the 7-year U.S. treasury
yield. The Company does not have sufficient company-specific historical and implied volatility information and it therefore estimates
its expected share volatility based on historical volatility information of reasonably comparable guideline public companies and itself.
The Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded
share price. Expected dividend yield is based on the fact that the Company has never paid cash dividends and its future ability to pay
cash dividends on its shares may be limited by the terms of any future debt or preferred securities. The Company has elected to account
for forfeitures as they occur.
The range of assumptions that the Company used to determine the
grant date fair value of employee and director options granted were as follows:
Schedule Of Range Of Assumptions |
|
|
|
|
|
|
|
For the 9 months ended September
30, 2022 |
|
Volatility |
|
|
70.91 – 75.32% |
|
Expected term in years |
|
|
6.92 – 7 |
|
Dividend rate |
|
|
0% |
|
Risk-free interest rate |
|
|
1.58 – 1.75% |
|
Share price |
|
|
$5.03 – $9.42 |
|
Fair value of option on grant date |
|
|
$3.31 – $6.18 |
|
The table below shows the number of options granted covering an
equal number of the Company’s Class A ordinary shares and the weighted-average grant date fair value of the options granted:
Schedule of Option Outstanding | |
| | | |
| | |
| |
Number of options | |
Weighted average Grant date fair value per share |
Options outstanding December 31, 2021 | |
| — | | |
| — | |
Granted | |
| 2,128,554 | | |
$ | 5.21 | |
Vested | |
| (64,278 | ) | |
$ | 3.31 | |
Forfeited | |
| — | | |
| — | |
Options outstanding September 30, 2022 | |
| 2,064,276 | | |
$ | 5.21 | |
There were 2,064,276 unvested employee and director
options outstanding as of September 30, 2022. Total expense recognized related to the employee and director share options was €2.22
million for the period ended September 30, 2022. Total unamortized compensation expense related to employee and director share options
was €9.01 million as of September 30, 2022, expected to be recognized over a remaining weighted average vesting period
of 2.92 years as of September 30, 2022.
Incentive shares
As part of their compensation package, the non-executive directors
that were appointed in December 2020 were granted 5,000 shares for each year of service to the Company.
Schedule of Incentive shares | |
| | | |
| | |
| |
Number of shares | |
Weighted average Grant date fair value per share |
Incentive shares outstanding December 31, 2021 | |
| 30,000 | | |
$ | 23 | |
Granted | |
| — | | |
$ | — | |
Vested | |
| — | | |
$ | — | |
Forfeited | |
| (25,000 | ) | |
$ | — | |
Incentive shares outstanding September 30, 2022 | |
| 5,000 | | |
$ | 23 | |
The above shares vest at the discretion of the board of directors.
In exchange for the share options that were granted above, the holders of the incentive shares agreed to forfeit their rights to incentive
shares relating to years two and three of their tenure as a non-executive director. The total expense for these shares recognized in the
nine month periods ended September 30, 2021 and 2021 was €0.26 million and €0, respectively.
As of September 30, 2022, there was no unrecognized share-based
payment expense related to the incentive shares. The shares have been recorded at their fair value at September 30, 2022.
Reconciliation to statement of profit or loss
Schedule of Reconciliation to statement of profit or loss | |
| | | |
| | |
€’000 | |
2022 | |
2021 |
2020 Earn-Out | |
| — | | |
| 4,730 | |
RSUs | |
| 412 | | |
| — | |
Incentive shares | |
| — | | |
| 166 | |
Options | |
| 2,221 | | |
| — | |
Share-based payment expense | |
| 2,633 | | |
| 4,896 | |
The Group earned no revenues and generated tax losses during
the nine month periods ended September 30, 2022 and 2021. An insignificant current tax expense was booked in the nine month period ended
September 30, 2022 which relates to taxes incurred in Portugal relating to motor vehicles (2021: €0). The Group did not recognized
any deferred tax expense for each period.
During the nine month periods ended September 30, 2022 and 2021,
the Group’s Portuguese operations were subject to a statutory tax rate of 21%. In Ireland, the headline corporate income tax rate
for trading companies is 12.5%, with a rate of 25% applicable to other non-trading sources.
As of September 30, 2022 and December 31, 2021, the Group
had unrecognized deferred tax assets of €3.6 million and €1.7 million respectively, mostly relating to tax losses incurred.
No deferred tax assets have been recognized due to the uncertainty of the Group’s ability to generate taxable profits in the foreseeable
future. The current assessment regarding the usability of deferred tax assets may change, depending on the Group’s taxable income
in future years.
Schedule of intangible assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product development in progress |
|
|
|
Intellectual property and patents registration |
|
|
|
Software |
|
|
|
Total |
|
2022 |
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
Cost |
|
|
|
|
|
|
|
|
At January 1, 2022 |
|
|
1,918 |
|
|
|
1,911 |
|
|
|
23 |
|
|
|
3,852 |
|
Additions – other* |
|
|
1,404 |
|
|
|
— |
|
|
|
41 |
|
|
|
1,445 |
|
At September 30, 2022 |
|
|
3,322 |
|
|
|
1,911 |
|
|
|
64 |
|
|
|
5,297 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortisation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At January 1, 2022 |
|
|
— |
|
|
|
— |
|
|
|
(5 |
) |
|
|
(5 |
) |
Amortisation charge |
|
|
— |
|
|
|
— |
|
|
|
(11 |
) |
|
|
(11 |
) |
At September 30, 2022 |
|
|
— |
|
|
|
— |
|
|
|
(16 |
) |
|
|
(16 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net book value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At September 30, 2022 |
|
|
3,322 |
|
|
|
1,911 |
|
|
|
48 |
|
|
|
5,281 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At January 1, 2021 |
|
|
288 |
|
|
|
1,911 |
|
|
|
4 |
|
|
|
2,203 |
|
Additions – other* |
|
|
1,630 |
|
|
|
— |
|
|
|
19 |
|
|
|
1,649 |
|
At December 31, 2021 |
|
|
1,918 |
|
|
|
1,911 |
|
|
|
23 |
|
|
|
3,852 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortisation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At January 1, 2021 |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Amortisation charge |
|
|
— |
|
|
|
— |
|
|
|
(5 |
) |
|
|
(5 |
) |
At December 31, 2021 |
|
|
— |
|
|
|
— |
|
|
|
(5 |
) |
|
|
(5 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net book value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At December 31, 2021 |
|
|
1,918 |
|
|
|
1,911 |
|
|
|
18 |
|
|
|
3,847 |
|
* |
The additions relate to materials acquired during the
period for the purpose of developing our HEVO technology. |
Intellectual property at September 30, 2022 and December 31, 2021 of €1.9 million and €1.9
million respectively, and product development costs of €3.3 million and €1.9 million respectively, are considered to be of indefinite
life and accordingly are not amortized. In line with the Group’s accounting policy, development expenditure is measured at cost
less accumulated amortisation and any accumulated impairment losses, unless the product development costs are still being used in product
development in which case it is considered indefinite useful life. During the fourth quarter of 2022, the Group began to amortise a significant
portion of the product development costs on the basis that they were no longer considered to be used in product development. These items
are being amortized over useful lives of between 3 and 5 years.
The Group considers that there have been no indicators of impairment
during the period. The annual impairment analysis will be performed as at December 31, 2022.
|
5. |
Property, plant and equipment |
|
|
|
Assets under construction |
|
|
|
Office and other equipment |
|
|
|
Right of use assets |
|
|
|
Total |
|
2021 |
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
Cost |
|
|
|
|
|
|
|
|
At January 1, 2021 |
|
|
6 |
|
|
|
— |
|
|
|
— |
|
|
|
6 |
|
Additions during the year |
|
|
17,155 |
|
|
|
185 |
|
|
|
1,111 |
|
|
|
18,451 |
|
At December 31, 2021 |
|
|
17,161 |
|
|
|
185 |
|
|
|
1,111 |
|
|
|
18,457 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At January 1, 2021 |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Charge for year |
|
|
— |
|
|
|
(28 |
) |
|
|
(318 |
) |
|
|
(346 |
) |
At December 31, 2021 |
|
|
— |
|
|
|
(28 |
) |
|
|
(318 |
) |
|
|
(346 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net book values |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At December 31, 2021 |
|
|
17,161 |
|
|
|
157 |
|
|
|
793 |
|
|
|
18,111 |
|
At December 31, 2020 |
|
|
6 |
|
|
|
— |
|
|
|
— |
|
|
|
6 |
|
Depreciation expense on property and equipment was €0.09 million and €0.03
million for the nine month periods ended September 30, 2022 and 2021, respectively. Assets under construction includes costs mostly related
to construction of the Group’s two Évora hydrogen plants, costs incurred on the Group’s HEVO-Sul project and its Benavente
production facility.
During the period ended September 30, 2022, the Group entered into a Grant agreement
with Agência para o Investimento e Comércio Externo de Portugal, E.P.E. relating to the Benavente production facility. The
Group submitted its first claims under this agreement during the nine month period ended September 30, 2022, which amounted to €0.8
million. Using the net presentation method available under IAS 20 Accounting for Government Grants and Disclosure of Government Assistance,
the Group has netted this amount against the carrying value of the asset.
|
6. |
Financial assets at fair value through profit or loss |
Schedule of Financial asset at fair value |
|
|
|
|
|
|
|
2022 |
|
|
|
|
€’000 |
|
January 1, 2021 |
|
|
— |
|
Investments during the year |
|
|
44,328 |
|
Redemptions |
|
|
(18,169 |
) |
Unrealized gains and losses |
|
|
47 |
|
Translation differences |
|
|
1,247 |
|
December 31, 2021 |
|
|
27,453 |
|
Redemptions |
|
|
(27,893 |
) |
Realized gains and losses |
|
|
(899 |
) |
Translation differences |
|
|
1,339 |
|
September 30, 2022 |
|
|
— |
|
The financial asset investments at fair value through profit or loss consist of short-term
investments in listed managed funds. These managed funds have daily liquidity. The investments are reported at fair value with unrealized
gains or losses recorded in the consolidated statements of operations and comprehensive loss. Any differences between the cost and fair
value of investments are represented by unrealized gains or losses. The Group exited all positions during the nine months ended September
30, 2022.
|
7. |
Prepayments and other receivables |
Schedule of Prepayments and other receivables |
|
|
|
|
|
|
|
|
|
|
|
2022 |
|
|
|
2021 |
|
|
|
|
€’000 |
|
|
|
€’000 |
|
Prepayments (1) |
|
|
2,808 |
|
|
|
4,575 |
|
VAT recoverable |
|
|
6,574 |
|
|
|
3,564 |
|
Grant receivable |
|
|
803 |
|
|
|
— |
|
Other receivables |
|
|
688 |
|
|
|
333 |
|
Prepayments and other receivables |
|
|
10,873 |
|
|
|
8,472 |
|
|
(1) |
Prepayments mostly consist of advance payments to vendors for payments relating to inventory ahead of receipt. |
|
8. |
Trade and other payables |
Schedule of trade and other receivables |
|
|
|
|
|
|
|
|
|
|
|
2022 |
|
|
|
2021 |
|
|
|
|
€’000 |
|
|
|
€’000 |
|
Trade payables |
|
|
1,865 |
|
|
|
1,029 |
|
Amounts owed to related parties (1) |
|
|
752 |
|
|
|
801 |
|
Lease liability – current |
|
|
470 |
|
|
|
389 |
|
Payroll taxes |
|
|
295 |
|
|
|
149 |
|
Other |
|
|
34 |
|
|
|
509 |
|
Trade and other payables |
|
|
3,416 |
|
|
|
2,877 |
|
|
(1) |
This amount relates to a balance owing to an affiliate, MagP Inovação, S.A. (“MagP”).
Please refer to the 2021 Form 20-F for details of the Group’s relationship with MagP. |
|
9. |
Inventory / Provisions for onerous contracts |
The Company records provisions for onerous contracts when it becomes probable that
the total contract costs will exceed total contract revenue. Before a provision for onerous contracts is recorded, the related assets
under construction are measured at their net realisable value and written-off if necessary. Onerous contracts are identified by monitoring
the progress of the contract together with the underlying programme status. An estimate of the related contract costs is made, which requires
significant and complex assumptions, judgements and estimates related to achieving certain performance standards.
Exolum
Work commenced on the Exolum project during the third quarter of 2022. Included in
the Group’s inventory balance at September 30, 2022 was an amount of €1.17 million that was directly attributable to the fulfilment
of this project. On review of the revised project costs, the Company expects this project to be loss making and has recorded an impairment
charge of €1.17 million against the project related inventory held on September 30, 2022. This impairment charge is included in cost
of sales. The losses for this project are now expected to range between €1.88 million and €2.58 million.
As part of the contract, the Group will provide three separate warranties as follows:
General
There is a general warranty period of two years from the date of construction of the
plant. On successful completion of this two-year period and final acceptance of the plant, ownership will pass to Exolum.
Equipment
The Company will provide warranties on the key equipment and components for periods
ranging between two and 20 years from the date of final completion. Certain items with longer warranty periods have many years of historical
performance data, while our own HEVO technology has shorter historical performance data.
Performance guarantees
The Company has agreed to performance related warranties covering both degradation over time
and specified energy yields for period raging between two and 25 years from the date of final acceptance.
In addition to the above impairment charge, the Company has recognized an onerous contract
provision of €0.71 million. The determination of provisions for onerous contracts, is based on best estimates. The above provision
does not include any amounts related to the general equipment warranties or performance guarantees. Together, the total expense recorded
for this project in the Group’s nine-month financials at September 30, 2022 is €1.88 million which reflects the Group’s
best estimate at this time of the total expected contract loss. If the final loss related to the completion of this project differs from
the above, the Company will adjust the provision accordingly.
The functional currency of the Company is the Euro and as the
exercise price of the Company’s share purchase warrants is fixed in US Dollars, these warrants are considered a liability as a variable
amount of cash in the Company’s functional currency will be received on exercise. Accordingly, these warrants are classified and
accounted for as a derivative liability at fair value through profit or loss.
As of September 30, 2022 and December 31, 2021, there were 8,869,633
warrants outstanding. The warrants entitle the holder to purchase one Class A ordinary share of Parent at an exercise price of $11.50
per share. Until warrant holders acquire the Parent’s Class A ordinary shares upon exercise of such warrants, they have no rights
with respect to the Parent’s Class A ordinary shares. The warrants expire on December 10, 2025, or earlier upon redemption or liquidation
in accordance with their terms.
On December 10, 2021, all non-tradeable warrants converted to tradable warrants having reached
the first anniversary of their issuance. None of the non-tradeable warrants were exercised during the year ended December 31, 2021. The
fair value of the tradeable warrants is determined with reference to the prevailing market price for warrants that are trading on the
NASDAQ under the ticker HTOOW.
Schedule of fair value of the tradeable warrants and non tradeable warrants |
|
|
|
|
|
|
|
|
Total no. of warrants |
|
In issue at December 31, 2020 |
|
|
|
9,929,139 |
|
Exercise of warrants during the period |
|
|
|
(1,059,506 |
) |
In issue at December 31, 2021 |
|
|
|
8,869,633 |
|
Exercise of warrants during the period |
|
|
|
— |
|
In issue at September 30, 2022 |
|
|
|
8,869,633 |
|
The fair value of the traded warrants as at September 30, 2022
and December 31, 2021 was $1.07 and $1.95, respectively. See reconciliation of fair values below.
Schedule of reconciliation of fair values |
|
|
|
|
|
|
|
€’000 |
|
Balance – January 1, 2021 |
|
|
52,932 |
|
Fair value movement on warrants exercised* |
|
|
3,211 |
|
Warrants exercised – foreign exchange differences** |
|
|
67 |
|
Fair value movement on warrants unexercised (including exchange differences)* |
|
|
(31,565 |
) |
Derecognition of warrant liability on exercise*** |
|
|
(9,374 |
) |
Balance – December 31, 2021 |
|
|
15,271 |
|
Fair value movement on warrants unexercised (including exchange differences)* |
|
|
(5,535 |
) |
Balance – September 30, 2022 |
|
|
9,736 |
|
* |
recognized in profit or loss - Adjustments to the fair value of derivatives – warrants |
** |
recognized in profit or loss - Other finance income |
*** |
recognized in equity – Share premium |
11. |
Financial instruments and risk management |
The Group’s operations expose it to various financial risks that include credit
risk, liquidity risk and market risk. The Group has a risk management framework in place which seeks to limit the impact of these risks
on the financial performance of the Group. It is the policy of the Group to manage these risks in a non-speculative manner.
These unaudited condensed consolidated financial statements do not include all financial
risk management information and disclosures required in the annual financial statements and should be read in conjunction with the 2021
Form 20-F. There have been no changes in the Group’s risk management policies in the period.
Accounting classifications and fair value
The Group uses the following hierarchy for determining and disclosing
the fair value of financial instruments by valuation technique:
|
● |
Level 1: quoted (unadjusted) prices in active markets for identical assets or
liabilities; |
|
● |
Level 2: other techniques for which all inputs which have a significant effect
on the recorded fair value are observable, either directly or indirectly; and |
|
● |
Level 3: techniques which use inputs that have a significant effect on the recorded
fair value that are not based on observable market data. |
The Company recognises transfers between levels of the fair value
hierarchy at the end of the reporting period during which the change has occurred. There were no transfers between fair value levels during
the period.
As at September 30, 2022, the tradeable warrants are measured
at fair value using Level 1 inputs. The fair value of the tradeable warrants is measured based on quoted market prices at each reporting
date. Until the Group disposed of all its positions, the short-term investments were previously measured at fair value using Level 1 inputs.
See notes 7 and 10 for the fair value analysis.
Schedule of unobservable inputs in fair value measurement within Level 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Carrying value |
|
Fair value |
|
|
|
Cash and receivables |
|
|
|
Liabilities |
|
|
|
Total carrying amount |
|
|
|
Level 1 |
|
|
|
Level 2 |
|
|
|
Level 3 |
|
|
|
Total |
|
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
3,610 |
|
|
|
— |
|
|
|
3,610 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Other receivables* |
|
|
394 |
|
|
|
— |
|
|
|
394 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Trade payables |
|
|
— |
|
|
|
(1,865 |
) |
|
|
(1,865 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Tradeable warrants |
|
|
— |
|
|
|
(9,736 |
) |
|
|
(9,736 |
) |
|
|
(9,736 |
) |
|
|
— |
|
|
|
— |
|
|
|
(9,736 |
) |
Other payables** |
|
|
— |
|
|
|
(1,592 |
) |
|
|
(1,592 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
4,004 |
|
|
|
(13,193 |
) |
|
|
(9,189 |
) |
|
|
(9,736 |
) |
|
|
— |
|
|
|
— |
|
|
|
(9,736 |
) |
|
|
Carrying value |
|
Fair value |
|
|
|
Cash and receivables |
|
|
|
Liabilities |
|
|
|
Total carrying amount |
|
|
|
Level 1 |
|
|
|
Level 2 |
|
|
|
Level 3 |
|
|
|
Total |
|
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
|
|
€’000 |
|
2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
7,681 |
|
|
|
— |
|
|
|
7,681 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Financial assets at FVTPL |
|
|
27,453 |
|
|
|
— |
|
|
|
27,453 |
|
|
|
27,453 |
|
|
|
|
|
|
|
|
|
|
|
27,453 |
|
Other receivables* |
|
|
333 |
|
|
|
— |
|
|
|
333 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Trade payables |
|
|
— |
|
|
|
(1,029 |
) |
|
|
(1,029 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Tradeable warrants |
|
|
— |
|
|
|
(15,271 |
) |
|
|
(15,271 |
) |
|
|
(15,271 |
) |
|
|
— |
|
|
|
— |
|
|
|
(15,271 |
) |
Other payables** |
|
|
— |
|
|
|
(1,687 |
) |
|
|
(1,687 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
35,467 |
|
|
|
(17,987 |
) |
|
|
17,480 |
|
|
|
12,182 |
|
|
|
— |
|
|
|
— |
|
|
|
12,182 |
|
* |
Prepayments and VAT have been excluded as they are not classified as a financial asset. |
** |
Employment taxes have been excluded as these are statutory
liabilities. |
Cash and cash equivalents including the short-term
bank deposits
For cash and cash equivalents, all of which have a maturity of
less than three months, the carrying value is deemed to reflect a reasonable approximation of fair value.
Other receivables and payables
For the receivables and payables with a remaining term of less
than one year or on demand balances, the carrying amount less impairment allowances, where appropriate, is a reasonable approximation
of fair value.
Financial assets at FVTPL
Financial assets at FVTPL are remeasured to fair value at each
reporting date. At September 30, 2022, all financial assets at FVTPL had be disposed of.
Foreign exchange risk
The Group uses the Euro as its functional currency. Foreign
exchange rate risk is the risk that the fair value of Group assets or liabilities, or future expected cash flows will fluctuate because
of changes in foreign currency exchange rates. While the Company’s shares are listed in US dollars, the currency of the primary
operating environment of the Group is the Euro, and its exposure to the risk of changes in foreign currency would arise primarily when
revenue or expense is denominated in a currency other than the Euro. The Company currently has no operations outside of the Eurozone,
so the effect of the translation of foreign operations is not significant to the Group. At September 30, 2022 and December 31, 2021, the
Company has USD and EUR cash balances of approximately $2.1 million and $22.9 million, respectively, and €1.1 million and €14.8
million, respectively. The following significant exchange rates have been applied during the period.
Schedule of significant exchange rates |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Average rate |
|
|
|
Period-end spot rate |
|
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Euro |
|
|
|
|
|
|
|
|
AUD |
|
|
|
1.5052 |
|
|
|
1.5767 |
|
|
|
1.50760 |
|
|
|
1.5615 |
|
USD |
|
|
|
1.0650 |
|
|
|
0.8356 |
|
|
|
0.97480 |
|
|
|
1.1326 |
|
12. |
Loss per ordinary share |
Schedule of Earnings / (loss) per share |
|
|
|
|
|
|
|
|
|
|
|
2022 |
|
|
|
2021 |
|
Basic loss per Class A ordinary share |
|
|
(0.80 |
) |
|
|
(0.12 |
) |
Diluted earnings/ (loss) per Class A ordinary share |
|
|
(0.80 |
) |
|
|
(0.12 |
) |
Number of ordinary shares used for loss per share (weighted average) |
|
|
|
|
|
|
|
|
Basic |
|
|
13,189,385 |
|
|
|
13,123,723 |
|
Diluted |
|
|
13,189,385 |
|
|
|
13,123,723 |
|
Basic loss per share is calculated by dividing the loss for the
year attributable to ordinary equity holders of the parent by the weighted average number of Class A ordinary shares outstanding during
the year.
Diluted loss per share is calculated by dividing the loss attributable
to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year plus the weighted
average number of Class A ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into Class
A ordinary shares.
The diluted loss per share reflects the basic loss per share since
the effects of potentially dilutive securities are anti-dilutive. For the periods included in these financial statements the Group was
loss-making, therefore, the following anti-dilutive instruments are excluded in the calculation of diluted weighted average number of
ordinary shares outstanding:
Schedule of weighted average number of ordinary shares |
|
|
|
|
|
|
|
|
|
|
|
2022 |
|
|
|
2021 |
|
Warrants |
|
|
8,869,633 |
|
|
|
8,869,633 |
|
RSUs - outstanding |
|
|
96,484 |
|
|
|
17,695 |
|
RSUs – vested but no ordinary shares issued |
|
|
20,853 |
|
|
|
15,000 |
|
Incentive shares |
|
|
5,000 |
|
|
|
30,000 |
|
Share options |
|
|
2,096,415 |
|
|
|
— |
|
2020 Earn-Out |
|
|
|
|
|
|
|
|
Ordinary shares |
|
|
— |
|
|
|
1,137,000 |
|
Warrants |
|
|
— |
|
|
|
1,137,000 |
|
The potential outstanding equity awards under the 2020 Earn-Out
arrangement expired on June 30, 2022 and none of the required conditions were met. Accordingly, none of the 2020 earn-out class A ordinary
shares were issued.
13. |
Commitments and contingencies |
In a prior period, a subsidiary of the Group entered into an agreement,
with MagP, a related party to deliver equipment, materials and assembling services in relation to the Groups other ongoing production
facilities. At September 30, 2022, the Group had a minimum commitment of approximately €2.52 million with MagP until the end of this
contract, March 31, 2023.
The costs paid by the Group on behalf of Fusion Fuel Spain (€0.3
million) have been treated as an advancement of this loan for accounting purposes. A further commitment of €0.8 million remains at
September 30, 2022.
There have been no significant events since the statement of financial position date
that would require disclosure or amendment to the unaudited condensed consolidated financial statements.
Schedule of Group companies |
|
|
|
Entity name |
Country of incorporation |
Principal activities |
Group interest at December 31, 2021 |
Fusion Fuel Portugal, S.A. |
Portugal |
Operating company |
100% |
Fuel Cell Évora, Unipessoal LDA |
Portugal |
Hydrogen production |
100% |
Fuel Cell Évora I, Unipessoal LDA |
Portugal |
Hydrogen production |
100% |
Fusion Fuel USA, Inc. |
United States |
No activity to date |
100% |
Fusion Fuel Spain, S.L. |
Spain |
Hydrogen production |
50% |
Fusion Fuel Australia, PTY Ltd |
Australia |
Hydrogen production |
100% |
Fusion Fuel Australia – Pilot PTY Ltd |
Australia |
Hydrogen production |
100% |
Hevo Sines, Unipessoal LDA (1) |
Portugal |
Hydrogen production |
N/A |
Hevo Sines II, Unipessoal LDA (2) |
Portugal |
Hydrogen production |
N/A |
Hevo Sines III, Unipessoal LDA (3) |
Portugal |
Hydrogen production |
N/A |
|
(1) |
Incorporated on January 12, 2022 |
|
(2) |
Incorporated on March 22, 2022 |
|
(3) |
Incorporated on April 14, 2022 |
16. |
Approval of financial statements |
The directors approved the unaudited condensed consolidated
financial statements on December 13, 2022.
The following management’s
discussion and analysis (this “MD&A”) provides information concerning our financial condition and results of operations
for the nine months ended September 30, 2022 and 2021 and should be read in conjunction with our audited consolidated financial statements
and the related notes included in Item 17 of our Annual Report on Form 20-F for the fiscal year ended December 31, 2021 (“Annual
Report”), “Financial Statements.” All terms used herein and not otherwise defined shall have the meanings ascribed
to them in the Annual Report.
The following discussion
contains forward-looking statements that reflect our future plans, estimates, belief, and expected performance. The forward-looking statements
are dependent upon events, risks and uncertainties that may be outside our control. Our actual results could differ materially from those
discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed elsewhere
in our Annual Report, particularly in Item 3.D of the Annual Report, “Risk Factors,” and in the “Cautionary Note Regarding
Forward-Looking Statements” set forth below. In light of these risks, uncertainties and assumptions, the forward-looking events
discussed may not occur.
Overview
Fusion Fuel serves as a holding
company for the Fusion Fuel business. Fusion Fuel’s mission is to produce hydrogen with zero carbon emissions, thereby contributing
to a future of sustainable and affordable clean energy and the reversal of climate change. Fusion Fuel produces green hydrogen with components
built in-house and in partnership with MagP Inovação, S.A. (“MagP”).
The collaboration with MagP secured production capacity of certain concentrated photovoltaic technology
(“CPV”) solar tracking materials for projects through 2021, and currently complements in-house production capacity
of such materials for our projects. Our in-house production facility went live during the second quarter of 2022.
Fusion Fuel’s business
plan includes the sale of technology to parties interested in generating green hydrogen at an attractive cost (including to natural gas
networks, ammonia producers, oil refineries, and other similar customers), the development of hydrogen plants to be operated by Fusion
Fuel and active management of the portfolio of such hydrogen plants as assets, and the sale of green hydrogen as an output with pre-defined
Hydrogen Purchase Agreements.
To date, Fusion Fuel’s
business activity has primarily been financed by the capital in connection with its business combination with HL Acquisition Corp. (“HL”),
and the related private placement, in December 2020. Fusion Fuel expects both its capital and operating expenditures to significantly
increase in connection with its ongoing activities, as Fusion Fuel:
|
● |
builds out its in-house manufacturing facilities and purchases related equipment; |
|
● |
commercializes the HEVO-Solar technology and hydrogen plants; |
|
● |
continues to invest in its technology; |
|
● |
increases marketing and business development activities, including travel costs
and industry association membership fees; |
|
● |
maintains and improves its operational, financial and management information
systems; |
|
● |
hires additional key personnel; |
|
● |
maintains, expands, and protects its intellectual property portfolio; and |
|
● |
Continues to operate as a public company. |
Parent has generated no revenue to date. As reported,
in September 2021, we entered into our first third party technology sale agreement with Exolum, a leading supplier of specialist storage,
handling and transport for bulk liquids and gases. Work commenced on this project during the third quarter of 2022 and is expected to
be completed during the first quarter of 2023. The contract price included both fixed and variable elements and we expect to earn revenues
of approximately €1.9 million, which will be payable once certain conditions are met, including equipment warranties and performance
guarantees covering both degradation over time and specified energy yields. Upon entering into this contract, we expected that this project
would either have a low margin (if at all) or operate at a loss. As a result, we informally agreed with Exolum at the time, and again
more recently, to pursue innovation grant awards that could mitigate any loss. Nevertheless, we believed this contract was a key strategic
milestone for the Company for the following reasons:
| · | At the time, it was the first project of its kind for the Company and as such represented proof of concept of having an integrated
hydrogen production plant with a hydrogen refueling station; |
| · | The latest version of our HEVO-Solar technology was still being developed and being able to enter such an agreement without having
a track record provided third party support in what we believed our technology could achieve; and |
| · | It was seen as an important gateway into the Spanish market, by being able to develop and install a plant in a market with a strong
hydrogen agenda, in conjunction with a strategic partner like Exolum. |
When pricing this contract, we made an estimate of the raw material and
production costs, however, on review of such project costs, we revised our estimate and now currently expect that this project will
result in a loss ranging from approximately €1.88 to €2.58 million. We continue to work in conjunction with Exolum to source grant
funding given that this will be the first demonstrator plant of its kind in Spain. Based on our previous record with grant awards, we
would expect any such award to offset a significant portion of the expected losses, although there can be no assurance we will receive
any such grant awards. We continue to review the project costs but given current information, we have recorded an impairment charge of
approximately €1.2 million against the inventory held on September 30, 2022, that is directly attributable to fulfilling this project.
In addition, we have recognized an onerous loss provision of approximately €0.7 million. Together, the total expense recorded for
this project in the nine-months ended September 30, 2022, was approximately €1.9 million. This project has been of significant value
in building our Iberian pipeline and we believe that any loss (if we are unable to offset it with grants) will be offset by the business
opportunities created for the Company.
For the nine months
ended September 30, 2022, Parent generated a total comprehensive loss of approximately €10.6 million, primarily consisting of administration
expenses of approximately €11.57 million, share based payment expense of approximately €2.63 million and expenses related to
the Exolum project of approximately €1.9 million, partially mitigated by €5.54 million of fair value gains on its derivative
financial instruments (Warrants) and a foreign exchange gain of approximately €1.48 million generated during the period.
For the nine months ended
September 30, 2021, Parent generated total comprehensive loss of approximately €1.58 million, primarily consisting of administration
expenses of approximately €4.92 million and share based payment expense of approximately €14.69 million, partially mitigated
by a foreign exchange gain of approximately €1.93 million generated during the period.
For each of the nine months
ended September 30, 2022, and 2021, there was no cost of revenue, except for the above impairment charge recorded for Exolum during the
nine months ended September 30, 2022. Once Fusion Fuel commences internal commercial production, cost of revenue is expected to include
direct parts, material and labor costs, manufacturing overhead, including amortized tooling costs and depreciation of facilities, cost
of hydrogen production, shipping and logistics costs and reserves for estimated warranty expenses.
For the nine months ended
September 30, 2022, and 2021, research and development (“R&D”) expenses consisted of €3.04 million and €2.29
million, respectively, primarily consisting of:
|
● |
Fees paid to third parties such as consultants and contractors for outside development; |
|
● |
Expenses related to materials, supplies and third-party services; |
|
● |
In-house development of our propriety HEVO-Solar technology; |
|
● |
Personnel-related expenses, including salaries, benefits, and stock-based
compensation expense, for personnel in the
engineering and research functions; and |
|
● |
Depreciation for prototyping equipment and R&D facilities. |
We expect R&D costs to
gradually increase for the foreseeable future as we progress on projects due to continued investment in R&D activities to achieve
our business plans.
Parent has funded the activities
of the Fusion Fuel business using its own reserve of capital. To date, no grant amounts claimed have been received and these are still
under review. Subsequent to September 30, 2022, VAT receipts of €3.17 million have been received.
Key Factors Affecting Operating Results
We believe that our performance
and future success depend on several factors that present significant opportunities for us but also pose risks and challenges, including
those discussed below and in the section of the Annual Report titled “Risk Factors.”
Business Combination and Public Company Costs
On December 10, 2020, we consummated
the business combination among Parent, HL, and Fusion Fuel Portugal. Fusion Fuel Portugal was deemed the accounting predecessor of the
Parent and the successor SEC registrant, meaning that Fusion Fuel Portugal’s financial statements for previous periods will be disclosed
in Parent’s periodic reports filed with the SEC.
As a consequence of the transactions
with HL, Parent became an SEC-registered public company and its class A ordinary shares and Warrants are listed on Nasdaq, which has required
Parent and Fusion Fuel Portugal, as the operating company, to hire additional personnel and implement procedures and processes to address
public company regulatory requirements and customary practices. Parent and Fusion Fuel Portugal each expect to incur additional annual
expenses as a result of Parent becoming an SEC-registered and Nasdaq-listed public company for, among other things, directors’ and
officers’ liability insurance, director fees and additional internal and external accounting and legal and administrative resources,
including increased audit and legal fees.
Launch of Fusion Fuel’s Hydrogen Generator,
the HEVO-Solar, and First Green Hydrogen Plants
Fusion Fuel expects to derive
revenue from the development of its first green hydrogen plant - the Evora Project (H2Evora & GreenGas). Prior to installing any HEVO-Solar
units, Fusion Fuel was required to obtain all the construction permits, hydrogen production licenses and land rental agreements (the “Plant
Permits”) for any such plant. H2Evora consists of 15 HEVO-Solar generators armed with Fusion Fuel’s 2021 generation of the
HEVO micro-electrolyzer. H2Evora also includes state-of-the-art hydrogen purification, compression and storage systems, as well as
a Ballard fuel cell to convert the green hydrogen into electricity to be fed into the national grid. Installation at H2Evora is complete
and our HEVO-Solar generators have been operating continuously since late 2021. The facility received formal commissioning during the
fourth quarter of 2022. This was not only the first plant to create green hydrogen in Iberia, but also the first plant producing
and using green hydrogen as an energy storage medium all in one integrated facility.
On November 10, 2022, the Company
announced that it had successfully commissioned its H2Évora plant. The demonstration project, comprised of 15 HEVO-Solar units
and associated balance of plant equipment, will produce 15 tons of green hydrogen per year and avoid the emission of 135 tons of CO2 annually.
The facility includes a 200-kilowatt FCwaveTM fuel cell module supplied by Ballard Power Systems (“Ballard”), which
is used to convert its green hydrogen into electricity, enabling Fusion Fuel to sell power into the electric grid during periods of peak
demand. We believe the integration of Fusion Fuel’s solar-to-hydrogen HEVO solution and Ballard’s fuel cell technology is
a powerful proof of concept for the use of hydrogen as a flexible energy storage vector and off-grid power supply.
The GreenGas project consists
of 40 HEVO-Solar generators which will produce approximately 45 tons of green hydrogen per year. A portion of the HEVO-Solar generators
will be outfitted with the next generation HEVO-Night, which will unlock the production of green hydrogen using renewable energy sources
overnight or during periods of low or no solar irradiation. The GreenGas plant will be connected to the Autonomous Regasification Unit
of the City of Evora. The green hydrogen produced will demonstrate two use-cases:
|
● |
Direct injection into the Evora natural gas network to pilot hydrogen blending.
All of the solar tracker structures are already in place, and we are waiting on deployment of the HEVO micro-electrolyzers as well as
some Balance of Plant equipment. |
|
● |
Compression and bottling in cylinders for sale to industrial users. |
This will be Portugal’s first utility-scale
project to produce green hydrogen from solar energy and blend green hydrogen at scale into a local natural gas distribution network. Installation
of this facility is currently underway.
During the third quarter of
2022, Fusion Fuel commenced construction work on its first third-party technology sale. Fusion Fuel and Exolum will develop a turnkey
solar-to-hydrogen plant to supply green hydrogen to Madrid, Spain. Exolum is a leading supplier of specialist storage, handling and transport
for bulk liquids and gases, with one of the most comprehensive ranges of tankage in Europe. The project will have 21 HEVO-Solar units
along with a co-located refueling station, which will serve as proof of concept of hydrogen for mobility applications. This facility will
also feature the latest generation HEVO micro-electrolyzer capable of leveraging other sources of renewable energy to produce green
hydrogen overnight and during periods of low solar radiation, which are expected to double the productive output of the facility. The
construction of this solar-to-hydrogen plant is expected to be completed during the first quarter of 2023 with commissioning expected
to take place during the same quarter.
Fusion Fuel will begin construction
work on its second and larger hydrogen plant, known as the HEVO-Sul Project, which, in addition to requiring the same Plant Permits, is
also expected to require approximately €12m of capital expenditure which we expect to utilize working capital for such expenditures.
The project has already been granted the required environmental permits from the applicable Portuguese permitting agency and a final investment
decision is expected in the first half of 2023.
The HEVO-Sul project consists of 178 HEVO-Solars located
in Sines, Portugal. There is one other current project in Sines where Fusion Fuel is the provider of electrolyzer technology to the client.
This project would provide 62 units for KEME Energy, a Portuguese developer of renewable energy projects, to supply green hydrogen for
several industrial applications.
Grant funding of €4.3 million has been approved
for our HEVO-Sul project (178 HEVO-Solars) which has a total projected cost of approximately €12 million. In the third quarter of
2021, the grants for the other remaining project with KEME Energy, with projected costs of approximately €2.5 million, has been approved.
The grant is expected to be received throughout the execution life of the project which is expected to be in 2023. These two projects
taken together will require approximately €14.5 million of capital expenditure. We expect the installation of the systems for both
projects to occur throughout 2023 once construction permits have been approved and granted, which is expected to occur early in the first
quarter of 2023.
On September 29, 2022, the Company announced that it
had entered into a technology sale agreement with Gedisol Energiá, Sociedad Limitada a Spanish developer, to supply its innovative
solar-to-hydrogen systems for a 3.2 MW green hydrogen project located in Andalucía, Spain. The facility will consist of 144 HEVO-Solar
trackers that will generate an estimated 200 tonnes of green hydrogen per year. The Company expects to reach final investment decision
in the first half of 2023.
On October 6, 2022, the Company announced that it had
entered into a technology sale agreement with KEME Energy (“KEME”) to supply its solar-to-hydrogen system for a
1.22 MW green hydrogen project located in Sines, Portugal. The two companies had previously announced the execution of a collaboration
agreement in February 2022. The project, which secured a €2.4 million grant from Portugal’s POSEUR programme in late 2021,
will be developed in ZILS, the Sines Industrial and Logistics Zone, and will consist of 62 HEVO-Solar trackers that will generate an estimated
77 tonnes of green hydrogen per year. The hydrogen produced is expected to help meet local demand from customers in the nascent hydrogen
mobility sector. Fusion Fuel expects to begin construction of the facility in early 2023 and achieve commercial operation in the second
half of 2023.
On November 18, 2022, the Company announced that it
had entered into a commercial agreement with Duferco Energia SpA (“Duferco”) to jointly develop the green hydrogen
ecosystem in Italy and select markets in the MENA region. A subsidiary of Duferco Group, the multinational steel and commodity trading
company, Duferco Energia is focused on the management of energy production assets and marketing of energy services. The companies expect
to leverage Duferco’s local sales network, knowledge of local markets, and deep shipping and logistics expertise to develop a pipeline
of development opportunities and turnkey technology-sale projects. The inaugural project under the agreement is a 1.25 MW green hydrogen
pilot project to be developed at Duferco’s industrial site in Giammoro, Sicily. Fusion Fuel is expected to supply 50 of its HEVO-Solar
trackers for the proposed project, which would be installed in the first half of 2024. The facility would produce roughly 46 tonnes of
green hydrogen per year which would be used to power a molten carbonate fuel cell system, adding a unique and innovative aspect to the
project.
On November 21, 2022, the Company announced that four
projects in Spain, in which the Company is involved as a technology provider, have been pre-selected for up to €12.9 million in grant
funding. If successful, the grants will be awarded through the H2 Pioneros Program, which has a current year budget of €150
million and aims to support commercial projects across the renewable hydrogen value chain. H2 Pioneros is one of the first funding calls
under the Strategic Projects for Economic Recovery and Transformation (“PERTE”) program, a €6.9 billion financing tool
created under Spain’s recovery and resilience facility, to support projects and initiatives in renewable energy, green hydrogen,
and energy storage. Fusion Fuel is expected to supply a total of 423 HEVO-Solar units to the four projects, equivalent to 10.5 MW of electrolysis
capacity, which would reach final investment decision in 2023 and be delivered on a turnkey basis in 2024. These four projects are expected
to generate €31.7 million in revenue, of which an estimated €16.4 million would be derived from the sale of Fusion Fuel technology.
All four projects have secured land for their respective development, and the companies expect to commence permitting once the terms of
acceptance for the grants are signed. Three of the projects are focused on hydrogen refueling, a reflection of Fusion Fuel’s strategic
focus on the development of a mobility backbone throughout Iberia, while the fourth will produce green hydrogen for local industrial use.
On November 23, 2022, the Company announced its entry
into the centralized electrolyzer market with the introduction of its HEVO-Chain solution. The HEVO-Chain is a revolutionary innovation
in the design of centralized PEM electrolyzers. Rather than relying on a traditional cell-stack, the HEVO-Chain builds off Fusion Fuel’s
proprietary HEVO architecture, enabling the system to operate at higher efficiency – roughly 49 kWh / kg of hydrogen – and
avoid the losses that stem from more conventional electrolyzer stack designs. Each HEVO-Chain hydrogen unit consists of 16 HEVO micro-electrolyzers
interconnected along a string, representing 11.2 kW of electrolysis capacity and outputting 5.6 kg of hydrogen per day at a pressure of
4 bar. A planned second-generation unit is expected to increase the pressure at the outlet to 20-30 bar, among additional improvements.
As with the HEVO-Solar, the HEVO-Chain was built with modularity and scalability in mind – it is designed for a standard 19”
rack cabinet, allowing for up to eight units to be integrated seamlessly alongside the power electronics and water purification system.
The HEVO-Chain is currently undergoing comprehensive performance and reliability testing. The company expects the first HEVO-Chain units
to enter commercial use in 2024.
On November 28, 2022, the Company and Electus Energy announced
that the two companies had entered into an exclusive joint venture agreement to develop a large-scale green hydrogen project in Bakersfield,
California. The proposed project is a roughly 75 MW solar-to-hydrogen facility using Fusion Fuel´s HEVO technology, capable of producing
up to 9,300 tons of green hydrogen per year including nighttime operation. The project would require an estimated €175 million (or
approximately $180 million) in capital investment, with a final investment decision expected in early 2024 and commissioning in the first
half of 2025. Once operational, this project will provide enough hydrogen fuel to support over 1,000 Class 8 trucks or buses per day.
The companies have already entered into a land-lease agreement to secure 320 acres in Kern County, California for the project's development.
Fusion Fuel has engaged Black & Veatch to perform a concept study and is also working with Cornerstone Engineering and Headwaters
Solutions.
Any delays in the successful completion of the above
projects will impact Fusion Fuel’s ability to generate revenue.
Fusion Fuel has received interest in its technology
both from parties interested in developing their own hydrogen production plants, as well as parties interested in purchasing green hydrogen
as an end product. This interest comes from companies both within and outside of Portugal. Although Fusion Fuel expects the pipeline of
its announced projects to be an indicator of future performance, there can be no guarantees that any of the projects will succeed, be
completed or that any additional projects will be announced.
Critical Accounting Policies and Estimates
The unaudited condensed consolidated
financial statements have been prepared in accordance with IFRS accounting standards. The preparation of these unaudited condensed consolidated
financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and the disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements, as
well as the reported expenses incurred during the reporting periods.
Any estimates are based on
historical experience and on various other factors that management believes are reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.
While our significant accounting
policies are more fully discussed in our consolidated financial statements included in the Annual Report, we believe that the following
accounting policies are critical to the process of making significant judgments and estimates in the preparation of our consolidated financial
statements.
Derivative liabilities – warrants
Derivatives are initially recognized at their fair value
on the date the derivative contract is entered into, and transaction costs are expensed to profit or loss. The Company’s warrants
are subsequently re-measured at fair value at each reporting date with changes in fair value recognized in profit or loss.
As the exercise price of the Company’s share purchase
warrants is fixed in US dollars and the functional currency of the Company is the Euro, these warrants are considered a derivative, as
a variable amount of cash in the Company’s functional currency will be received on exercise. Accordingly, these share purchase warrants
are classified and accounted for as a derivative liability. For warrants that are tradeable, fair value is determined using market price
on the NASDAQ under the ticker HTOOW. All non-traded warrants became tradeable on December 10, 2021, the first anniversary of the issue
date.
When a warrant is exercised, the derivative liability
is then reclassified to share premium.
Share-based payment arrangements
The grant-date fair value of equity-settled share-based
payments arrangements granted to employees and non-employees is generally recognized as an expense, with a corresponding increase in equity,
over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect the numbers of awards for which the
related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized is based on the
number of awards that meet the related service and non-market performance conditions at the vesting date. For share-based payment awards
with non-vesting conditions, the grant-date fair value of the share-based payment is measured to reflect such conditions and there is
no true-up for differences between expected and actual outcomes.
Intangible assets – Development expenditures
Product development costs are
not amortized until such time that they are in use after which it is expected they will be amortized over their estimated useful lives
(three to five years).
Development expenditure is
capitalized only if the expenditure can be measured reliably, the product or process is technically and commercially feasible, future
economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset.
Otherwise, it is recognized in the profit or loss as incurred. Subsequent to initial recognition, development expenditure is measured
at cost less accumulated amortization and any accumulated impairment losses, unless the product development costs are still being used
in product development in which case it is considered indefinite useful life.
In accordance with IAS 36,
Impairment of Assets, management assesses the recoverability of Intellectual Property annually as they are currently deemed to be intangible
assets with indefinite useful lives.
This section should be read
in conjunction with note 3 of the financial statements included in the Annual Report.
|
B. |
Liquidity and Capital Resources |
At September 30, 2022, Parent
had a cash position of approximately €3.61 million, other assets of approximately €56.47 million, liabilities of approximately
€16.32 million and no open tax obligations. Our cash position was funded primarily from the net proceeds generated from the HL merger
and the concurrent private placement financing that closed on December 10, 2020, as well as proceeds of approximately $10.05 million from
the exercise of warrants during the first quarter of 2021.
Parent’s assets, in addition to cash and
cash equivalents, consist of advances to suppliers in the amount of approximately €2.81 million, which consists mostly of
amounts required to secure the future supply of raw materials and equipment for our hydrogen production plants. Parent’s
liabilities consist of accounts payable to suppliers in the amount of approximately €1.86 million, accruals in the amount of
approximately €1.56 million, provisions of approximately 0.71 million and warrants in the amount of approximately €9.74
million. The Group has no external debt as of September 30, 2022.
In a prior period, a subsidiary
of the Group entered into an agreement with MagP, a related party, to deliver equipment, materials and assembling services in relation
to the Groups other ongoing production facilities. At September 30, 2022, the Group had a minimum commitment of approximately €2.52
million with MagP until the expiration of this contract on March 31, 2023.
During 2021, the Group
extended a participating loan to finance the growth and working capital needs of Fusion Fuel Spain S.L, an entity in which the Company
has joint control. This loan facility has a term of five years and the maximum amount that can be drawn down is €2 million . €0.2
million had been drawn down during the nine month period ended September 30, 2022 and the costs paid by the Group on behalf of Fusion
Fuel Spain, €0.3 million, have been treated as an advancement of this loan for accounting purposes. An amount of €0.8 million
had yet to be drawn down at September 30, 2022.
In February 2022, the Company announced that its wholly
owned subsidiary, Fusion Fuel Portugal, S.A. secured nearly €10 million in grants for its industrial production facility in Benavente.
Under this grant agreement, the funding is split into two components: direct financial support for eligible expenses and tax credits available
to the company over a period of several years. The funding is provided to the Company as reimbursement of expenses incurred by the Company
in connection with the project and is paid to the Company after it has spent such amounts but no further conditions or approvals are necessary
for the Company to receive the reimbursements.
On May 19, 2022, the Company and Toshiba Energy Systems
and Solutions Corporation (“Toshiba ESS”) announced that they have signed a Memorandum of Understanding providing for the
companies to pursue technical and commercial opportunities in the fast-growing green hydrogen sector. As part of this collaboration, Fusion
Fuel will evaluate the use of Toshiba ESS membrane electrode assemblies (MEAs) in its proprietary Proton-Exchange Membrane (PEM) electrolyzers.
MEAs are a core component of PEM electrolyzers, and those under development by Toshiba ESS are highly cost-competitive and require significantly
less catalyst than conventional solutions. In addition, Toshiba ESS will explore using the local sales channels it has developed in areas
such as the thermal power business to expand sales of Fusion Fuel’s PEM electrolyzers in Australia and other countries. Furthermore,
the two companies will also explore potential collaboration for future sales of Toshiba ESS solid oxide electrolysis cells (“SOEC”),
which Toshiba ESS targets bringing to market in 2025.
On August 18, 2022, the Company announced that it had
received confirmation from the Portuguese government that it will receive an estimated €10 million grant as part of Component 14
(“C-14”) of the Portuguese Recovery and Resilience Plan to develop its 6.6MW HEVO-Industria green hydrogen project in Sines, Portugal.
C-14 is focused on accelerating the energy transition by supporting the production of hydrogen and other renewable gases.
On December 7, 2022, Parent announced that it had been
approved for a total of €36 million in grant funding for its “Sines Green Hydrogen Valley Alliance” through Component
5 (“C-05”) of Portugal´s Recovery and Resilience Plan. The component – Mobilizing Agendas for Business Innovation
– is intended to align stakeholders from across the entire value chain to develop the domestic green hydrogen ecosystem. The company
had previously disclosed that it had been selected for financing awards, subject to further negotiations with the Agenda Coordination
Commission. These discussions have now been concluded and Fusion Fuel has submitted the respective award contract duly signed and expects
to receive the award by mid-January 2023.
Of the €36 million awarded to the consortium,
€22.5 million will be allocated to Fusion Fuel’s H2 HEVO-SINES project, a 3,000 HEVO-Solar facility – equivalent to 75
MW of electrolysis capacity – that will be developed, owned, and operated by the company. Fusion Fuel has already secured 121 hectares
of land within the Sines area for the development of the project, which is expected to reach final investment decision and commence construction
in 2024. The green hydrogen to be produced is expected to be used in decarbonizing local industry, mobility applications, and for blending
into the natural gas grid. Another €3.5 million will be allocated to Fusion Fuel to fund research and development of its proprietary
electrolysis technology. The balance of the funding will be allocated to other projects within Fusion Fuel’s consortium for which
the Company is a technology partner, including those sponsored by KEME Energy, Transition2Green, and HyLAB Collaborative Laboratory.
At the Market Issuance Sales Agreement
On June 6, 2022, Parent entered into an At the Market Issuance Sales Agreement (the “ATM”)
with B. Riley Securities, Inc., Fearnley Securities Inc., and H.C. Wainwright & Co., LLC, pursuant to which the Company may offer
and sell, from time to time, through or to the agents, acting as agent or principal, class A ordinary shares of the Company having an
aggregate offering price of up to $30 million. Between July 11, 2022 and September 30, 2022, we sold 295,269 class A ordinary shares for
net proceeds of $2,204,959 at an average sales price of $7.35 per share. We paid $66,149 in commissions to the agents in connection with
these sales. Between October 3, 2022, and November 14, 2022, we sold an additional 386,657 class A ordinary shares for net proceeds of
$1,480,833 at an average sales price of $4.02 per share. We paid $44,425 in commissions to the agents in connection with these sales.
Management is of the opinion that the Company’s working capital at September 30, 2022,
and the receipt of grant funding that has been awarded and scheduled project related revenues will provide sufficient liquidity to fund
operations for at least one year after the date the financial statements are issued. In making this assessment, management has considered
the Group’s available cash resources, future financing options available to the Group, the planned operations of the Group and the
ability to adjust its plans if required.
The Group expects to seek additional funding in order
to continue to fund its operations through the end of 2023 and beyond. The Group expects to seek additional funding through public or
private financing of debt or equity or through strategic partnerships. The inability to obtain funding, as and when needed, would have
a negative impact on the Group’s financial conditions and ability to pursue its business strategies. If the Group is unable to obtain
funding, the Group could be forced to delay, reduce, or eliminate some or all of its research and development programs or strategic partnerships
efforts, which could adversely affect its business prospects, or the Group may be unable to continue operations. Although management intends
to pursue plans to obtain additional funding to finance its operations, there is no assurance that the Group will be successful in obtaining
sufficient funding on terms acceptable to the Group to fund continuing operations, if at all.
|
C. |
Research and Development, Patents and Licenses, etc. |
Fusion Fuel’s industry
and business require continuous innovation and improvement. To this end, the R&D team has already designed the next two generations
of the HEVO-Solar which, subject to necessary funding, the Company expects to develop. This innovation aims at not only improving the
efficiency of the product, but also reducing the costs of production. Continuous R&D is a core part of the ongoing strategy for Fusion
Fuel. For more information about Fusion Fuel’s R&D, see Item 4 “Business Overview – Research and Development”
in the Annual Report.
Other than the risks described
in Item 3.D. “Risk Factors” of the Annual Report, we are not aware of any trends, uncertainties, demands, commitments or events
since the beginning of our fiscal year 2021 that are reasonably likely to have a material effect on our net revenues, income from operations,
profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative
of future operating results or financial condition.
|
E. |
Off-Balance Sheet Arrangements |
Parent does not have any off-balance sheet arrangements
as of September 30, 2022.
|
F. |
Contractual Obligations |
Fusion Fuel Portugal has a
Production Agreement with MagP pursuant to which MagP guarantees a supply of all materials and installations for the CPV solar trackers
used in Fusion Fuel’s HEVO-Solars on an annual basis. Other than the obligation to pay for the minimum number of trackers to be
produced under this contract, which minimum amount is approximately €5.04 million, Fusion Fuel does not have any financial obligations
under this contract, contingent or otherwise, as the contract provides that MagP is to deliver a fixed number of Trackers. A fixed cost
per Tracker to be supplied by MagP is also stipulated in the contract. For more information relating to the contracts with MagP, see “Related
Party Transactions” in the Annual Report.
Parent does not have any significant
capital or other commitments, long-term obligations, or guarantees as of September 30, 2022.
This MD&A contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. See “Cautionary Note Regarding Forward-Looking
Statements” below.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Form 6-K contains or may contain forward-looking
statements as defined in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of
the Securities Exchange Act of 1934 (the “Exchange Act”) that involve significant risks and uncertainties. All statements
other than statements of historical facts are forward-looking statements. These forward-looking statements include information about our
possible or assumed future results of operations or our performance. These statements involve known and unknown risks, uncertainties and
other factors, including those listed under “Risk Factors” in the Company’s Annual Report on Form 20-F for the fiscal
year ended December 31, 2021, and in “Management’s Discussion and Analysis of Financial Condition and Results of Operation”
set forth above that may cause our actual results, performance or achievements to be materially different from those expressed or implied
by the forward-looking statements.
In some cases, these forward-looking statements can
be identified by words and phrases such as “may,” “should,” “intend,” “predict,” “potential,”
“continue,” “will,” “expect,” “anticipate,” “estimate,” “plan,”
“believe,” “is /are likely to” or the negative form of these words and phrases or other comparable expressions.
The forward-looking statements included in this Form 6-K relate to, among other things:
|
● |
our goals and growth strategies; |
|
● |
our future prospects and market acceptance of products and services; |
|
● |
our future business development, financial condition, and results of operations; |
|
● |
changes in our revenue, costs, or expenditures; |
|
● |
our expectations regarding the demand for, and market acceptance of, our products
and services; |
|
● |
general economic and business conditions in the markets in which we operate; |
|
● |
growth and competition in the markets in which we operate; |
|
● |
relevant government policies and regulations relating to our business and industry; |
|
● |
the length and severity of the COVID-19 pandemic, including its
impact on our business and on demand, project development, construction, operations, and maintenance, finance, and our global supply
chains, actions that may be taken by governmental authorities to contain the outbreak or treat its impacts, and the ability of our
customers, suppliers, vendors, and other counterparties to fulfill their contractual obligations to us; and |
|
● |
the assumptions underlying or related to any of the foregoing. |
These forward-looking statements involve various risks,
assumptions, and uncertainties. Although we believe that our expectations expressed in these forward-looking statements are reasonable,
our expectations may turn out to be incorrect. Our actual results could be materially different from or worse than our expectations. You
should read this Form 6-K and the documents that we refer to in this Form 6-K with the understanding that our actual future results may
be materially different from and worse than what we expect. Moreover, we operate in an evolving environment. New risk factors and uncertainties
emerge from time to time, and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the
impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements.
You should not rely upon forward-looking statements
as predictions of future events. The forward-looking statements made in this Form 6-K relate only to events or information as of the date
on which the statements are made in this Form 6-K. All forward-looking statements included herein attributable to us or other parties
or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in
this section. We undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future
events or otherwise, after the date of this Form 6-K or to reflect the occurrence of unanticipated events, except as otherwise required
by the U.S. federal securities laws.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Fusion Fuel Green PLC |
|
(Registrant) |
|
|
Date: December 13, 2022 |
/s/ Frederico Figueira de Chaves |
|
Frederico Figueira de Chaves |
|
Chief Financial Officer |
Fusion Fuel Green (NASDAQ:HTOO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Fusion Fuel Green (NASDAQ:HTOO)
Historical Stock Chart
From Jul 2023 to Jul 2024